BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571. [PMID: 25428505 DOI: 10.1038/nature13954] [Cited by in Crossref: 3422] [Cited by in F6Publishing: 3190] [Article Influence: 488.9] [Reference Citation Analysis]
Number Citing Articles
1 Mizrahi J, Pant S. Immunotherapy in Gastrointestinal Malignancies. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2020. pp. 93-106. [DOI: 10.1007/978-3-030-41008-7_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Letters 2019;458:123-35. [DOI: 10.1016/j.canlet.2019.05.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
3 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
4 Dahan R, Sega E, Engelhardt J, Selby M, Korman A, Ravetch J. FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell 2015;28:285-95. [DOI: 10.1016/j.ccell.2015.08.004] [Cited by in Crossref: 155] [Cited by in F6Publishing: 145] [Article Influence: 22.1] [Reference Citation Analysis]
5 Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74-80. [PMID: 25838376 DOI: 10.1126/science.aaa6204] [Cited by in Crossref: 939] [Cited by in F6Publishing: 879] [Article Influence: 134.1] [Reference Citation Analysis]
6 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
7 Twitty CG, Huppert LA, Daud AI. Prognostic Biomarkers for Melanoma Immunotherapy. Curr Oncol Rep 2020;22:25. [PMID: 32048065 DOI: 10.1007/s11912-020-0886-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Capalbo C, Scafetta G, Filetti M, Marchetti P, Bartolazzi A. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. Int J Mol Sci 2019;20:E1607. [PMID: 30935099 DOI: 10.3390/ijms20071607] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
9 Xiao X, Mo H, Tu K. CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. Int Immunopharmacol 2020;89:107043. [PMID: 33039961 DOI: 10.1016/j.intimp.2020.107043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Vinayan A, Glynne-Jones R. Anal cancer - What is the optimum chemoradiotherapy? Best Pract Res Clin Gastroenterol 2016;30:641-53. [PMID: 27644911 DOI: 10.1016/j.bpg.2016.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Corgnac S, Malenica I, Mezquita L, Auclin E, Voilin E, Kacher J, Halse H, Grynszpan L, Signolle N, Dayris T, Leclerc M, Droin N, de Montpréville V, Mercier O, Validire P, Scoazec JY, Massard C, Chouaib S, Planchard D, Adam J, Besse B, Mami-Chouaib F. CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. Cell Rep Med 2020;1:100127. [PMID: 33205076 DOI: 10.1016/j.xcrm.2020.100127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
12 Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest 2018;128:1338-54. [PMID: 29480817 DOI: 10.1172/JCI93303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
13 Wakabayashi Y, Usui Y, Kawakami S, Hirose T, Goto H. Neovascular age-related macular degeneration inactivated during systemic administration of an immune checkpoint inhibitor pembrolizumab for lung cancer. Acta Ophthalmol 2021. [PMID: 34233093 DOI: 10.1111/aos.14969] [Reference Citation Analysis]
14 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Reference Citation Analysis]
15 Pachynski RK, Wang P, Salazar N, Zheng Y, Nease L, Rosalez J, Leong WI, Virdi G, Rennier K, Shin WJ, Nguyen V, Butcher EC, Zabel BA. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment. Front Immunol 2019;10:983. [PMID: 31139180 DOI: 10.3389/fimmu.2019.00983] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
16 Koelzer VH, Glatz K, Bubendorf L, Weber A, Gaspert A, Cathomas G, Lugli A, Zippelius A, Kempf W, Mertz KD. [The pathology of adverse events with immune checkpoint inhibitors]. Pathologe 2017;38:197-208. [PMID: 28421272 DOI: 10.1007/s00292-017-0281-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Simon SCS, Hu X, Panten J, Grees M, Renders S, Thomas D, Weber R, Schulze TJ, Utikal J, Umansky V. Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. Oncoimmunology 2020;9:1727116. [PMID: 32117594 DOI: 10.1080/2162402X.2020.1727116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
18 Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. Am J Clin Pathol. 2017;148:441-449. [PMID: 29069274 DOI: 10.1093/ajcp/aqx092] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
19 Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One 2020;15:e0224775. [PMID: 32084139 DOI: 10.1371/journal.pone.0224775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
21 Harvey NT, Millward M, Macgregor K, Bucat RP, Wood BA. Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. Am J Dermatopathol 2016;38:e159-62. [PMID: 27870733 DOI: 10.1097/DAD.0000000000000668] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
22 Ngamcherdtrakul W, Reda M, Nelson MA, Wang R, Zaidan HY, Bejan DS, Hoang NH, Lane RS, Luoh SW, Leachman SA, Mills GB, Gray JW, Lund AW, Yantasee W. In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. Adv Mater 2021;33:e2100628. [PMID: 34118167 DOI: 10.1002/adma.202100628] [Reference Citation Analysis]
23 O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16:151-167. [PMID: 30523282 DOI: 10.1038/s41571-018-0142-8] [Cited by in Crossref: 328] [Cited by in F6Publishing: 322] [Article Influence: 109.3] [Reference Citation Analysis]
24 Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J, Ferté C. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15:748-62. [DOI: 10.1038/s41571-018-0111-2] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 40.0] [Reference Citation Analysis]
25 Pezeshki PS, Rezaei N. Immune checkpoint inhibition in COVID-19: risks and benefits. Expert Opin Biol Ther 2021;:1-7. [PMID: 33543652 DOI: 10.1080/14712598.2021.1887131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL. Hodgkin lymphoma. Nat Rev Dis Primers 2020;6:61. [PMID: 32703953 DOI: 10.1038/s41572-020-0189-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
27 Yang Q, Shen R, Xu H, Shi X, Xu L, Zhang L, Fan X, Jin X. Comprehensive analyses of PBRM1 in multiple cancer types and its association with clinical response to immunotherapy and immune infiltrates. Ann Transl Med 2021;9:465. [PMID: 33850862 DOI: 10.21037/atm-21-289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Jiang Q, Ghafoor A, Mian I, Rathkey D, Thomas A, Alewine C, Sengupta M, Ahlman MA, Zhang J, Morrow B, Steinberg SM, Pastan I, Hassan R. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med 2020;12:eaaz7252. [PMID: 32611684 DOI: 10.1126/scitranslmed.aaz7252] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
29 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Reference Citation Analysis]
30 Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 2016;7:140. [PMID: 27833586 DOI: 10.3389/fendo.2016.00140] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
31 Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, Ji J. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res 2020;8:35. [PMID: 32864132 DOI: 10.1186/s40364-020-00212-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
32 Yang CY, Lin MW, Chang YL, Wu CT, Yang PC. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. Eur J Cancer 2016;57:91-103. [PMID: 26901614 DOI: 10.1016/j.ejca.2015.12.033] [Cited by in Crossref: 79] [Cited by in F6Publishing: 88] [Article Influence: 13.2] [Reference Citation Analysis]
33 Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, Wilkinson RW. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget 2016;7:18508-20. [PMID: 26918344 DOI: 10.18632/oncotarget.7610] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
34 Wang L, Liu Y, Liu H, Tian H, Wang Y, Zhang G, Lei Y, Xue L, Zheng B, Fan T, Zheng Y, Tan F, Xue Q, Gao S, Li C, He J. The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. Aging (Albany NY) 2020;13:1383-409. [PMID: 33472175 DOI: 10.18632/aging.202355] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Hickey RM, Kulik LM, Nimeiri H, Kalyan A, Kircher S, Desai K, Riaz A, Lewandowski RJ, Salem R. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. J Vasc Interv Radiol 2017;28:1487-94. [PMID: 28912090 DOI: 10.1016/j.jvir.2017.07.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
36 Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy. Sci Rep 2018;8:1058. [PMID: 29348598 DOI: 10.1038/s41598-018-19548-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
37 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
38 Cascio MJ, Whitley EM, Sahay B, Cortes-Hinojosa G, Chang LJ, Cowart J, Salute M, Sayour E, Dark M, Sandoval Z, Mitchell DA, Milner RJ. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. Vet Immunol Immunopathol 2021;232:110169. [PMID: 33387703 DOI: 10.1016/j.vetimm.2020.110169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015;7:2397-414. [PMID: 26690220 DOI: 10.3390/cancers7040900] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
40 Rajakulendran T, Adam DN. Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther 2015;9:2883-6. [PMID: 26082618 DOI: 10.2147/DDDT.S78036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
41 Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015;33:1079-86. [PMID: 26389576 DOI: 10.1038/nbt.3349] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 11.9] [Reference Citation Analysis]
42 Shamseddine A, Zeidan YH, Kreidieh M, Khalifeh I, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Jamali F, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Khoury C, El Husseini Z, Charafeddine M, Al Darazi M, Geara F. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma. BMC Cancer 2020;20:831. [PMID: 32873251 DOI: 10.1186/s12885-020-07333-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Ung C, Kockx MM. Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmune™ Methodology. Expert Review of Precision Medicine and Drug Development 2016;1:9-24. [DOI: 10.1080/23808993.2016.1140005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
44 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
45 Shu Y, Wu X, Shen J, Luo D, Li X, Wang H, Tang YT. Tumor Mutation Burden Computation in Two Pan-Cancer Precision Medicine Next-Generation Sequencing Panels. Journal of Computational Biology 2020;27:1553-60. [DOI: 10.1089/cmb.2019.0055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Idorn M, Thor Straten P. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. Cells 2018;7:E108. [PMID: 30126117 DOI: 10.3390/cells7080108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
47 Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lennartz M, Fraune C, Nickelsen V, Fehrle W, Göbel C, Weidemann S, Clauditz T, Lebok P, Möller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebke AM, Büscheck F, Höflmayer D, Wilczak W, Burandt E, Hinsch A. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cell Oncol (Dordr) 2020;43:421-30. [PMID: 32141029 DOI: 10.1007/s13402-020-00496-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
48 Blanchard L, Girard JP. High endothelial venules (HEVs) in immunity, inflammation and cancer. Angiogenesis 2021. [PMID: 33956259 DOI: 10.1007/s10456-021-09792-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Hu M, Wang YM, Wang Y, Zhang GY, Zheng G, Yi S, O'Connell PJ, Harris DC, Alexander SI. Regulatory T cells in kidney disease and transplantation. Kidney Int 2016;90:502-14. [PMID: 27263492 DOI: 10.1016/j.kint.2016.03.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
50 Liu SL, Bian LJ, Liu ZX, Chen QY, Sun XS, Sun R, Luo DH, Li XY, Xiao BB, Yan JJ, Lu ZJ, Yan SM, Yuan L, Tang LQ, Li JM, Mai HQ. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. J Immunother Cancer 2020;8:e000205. [PMID: 32303611 DOI: 10.1136/jitc-2019-000205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
51 de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B. TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 2018;33:60-74.e6. [PMID: 29316433 DOI: 10.1016/j.ccell.2017.11.019] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 28.3] [Reference Citation Analysis]
52 Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015;14:149. [PMID: 26245467 DOI: 10.1186/s12943-015-0421-2] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 17.7] [Reference Citation Analysis]
53 Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 2021;101:102227. [PMID: 34656019 DOI: 10.1016/j.ctrv.2021.102227] [Reference Citation Analysis]
54 Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in personalized cancer immunotherapy. Breast Cancer. 2017;24:16-24. [PMID: 27000871 DOI: 10.1007/s12282-016-0688-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
55 Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019;40:511-23. [PMID: 31053497 DOI: 10.1016/j.it.2019.04.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 24.7] [Reference Citation Analysis]
56 Huynh TG, Morales-Oyarvide V, Campo MJ, Gainor JF, Bozkurtlar E, Uruga H, Zhao L, Gomez-Caraballo M, Hata AN, Mark EJ, Lanuti M, Engelman JA, Mino-Kenudson M. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. J Thorac Oncol 2016;11:1869-78. [PMID: 27568346 DOI: 10.1016/j.jtho.2016.08.134] [Cited by in Crossref: 53] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
57 Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016;5:e1052212. [PMID: 27622011 DOI: 10.1080/2162402x.2015.1052212] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
58 Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB, Fox BA. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer 2015;3:47. [PMID: 26500776 DOI: 10.1186/s40425-015-0091-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 11.1] [Reference Citation Analysis]
59 Sharma M, Yang Z, Miyamoto H. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine (Baltimore) 2019;98:e17257. [PMID: 31567999 DOI: 10.1097/MD.0000000000017257] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
60 Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond) 2020;40:135-53. [PMID: 32301585 DOI: 10.1002/cac2.12023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 26.5] [Reference Citation Analysis]
61 Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy 2015;7:777-92. [PMID: 26250412 DOI: 10.2217/imt.15.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
62 Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol 2020;21:1653-60. [PMID: 33271094 DOI: 10.1016/S1470-2045(20)30486-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
63 Sylvestre M, Saxby CP, Kacherovsky N, Gustafson H, Salipante SJ, Pun SH. Identification of a DNA Aptamer That Binds to Human Monocytes and Macrophages. Bioconjug Chem 2020;31:1899-907. [PMID: 32589412 DOI: 10.1021/acs.bioconjchem.0c00247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Granier C, Karaki S, Roussel H, Badoual C, Tran T, Anson M, Fabre E, Oudard S, Tartour E. Immunothérapie des cancers : rationnel et avancées récentes. La Revue de Médecine Interne 2016;37:694-700. [DOI: 10.1016/j.revmed.2016.05.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
65 Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, Wildgruber M. The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol 2019;16:442-58. [PMID: 30718844 DOI: 10.1038/s41571-019-0169-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
66 Lim JS, Sundar R, Chénard-poirier M, Lopez J, Yap TA. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers in Medicine 2017;11:53-67. [DOI: 10.2217/bmm-2016-0228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
67 Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget 2018;9:18985-96. [PMID: 29721177 DOI: 10.18632/oncotarget.24867] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
68 Wang Q, Xie B, Liu S, Shi Y, Tao Y, Xiao D, Wang W. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy? Front Immunol 2021;12:773168. [PMID: 35003090 DOI: 10.3389/fimmu.2021.773168] [Reference Citation Analysis]
69 Chen JH, Yang JL, Chou CY, Wang JY, Hung CC. Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. Sci Rep 2018;8:9686. [PMID: 29946182 DOI: 10.1038/s41598-018-27994-x] [Reference Citation Analysis]
70 Mastracci L, Fontana V, Queirolo P, Carosio R, Grillo F, Morabito A, Banelli B, Tanda E, Boutros A, Dozin B, Gualco M, Salvi S, Romani M, Spagnolo F, Poggi A, Pistillo MP. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunol Immunother 2020;69:653-62. [PMID: 32025849 DOI: 10.1007/s00262-020-02494-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
71 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
72 Gao J, Zhang H, Zhou F, Hou B, Chen M, Xie Z, Yu H. Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. Chinese Chemical Letters 2021;32:1929-36. [DOI: 10.1016/j.cclet.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Bulgarelli J, Tazzari M, Granato AM, Ridolfi L, Maiocchi S, de Rosa F, Petrini M, Pancisi E, Gentili G, Vergani B, Piccinini F, Carbonaro A, Leone BE, Foschi G, Ancarani V, Framarini M, Guidoboni M. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors. Front Immunol 2019;10:2353. [PMID: 31649669 DOI: 10.3389/fimmu.2019.02353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
74 Roudko V, Greenbaum B, Bhardwaj N. Computational Prediction and Validation of Tumor-Associated Neoantigens. Front Immunol 2020;11:27. [PMID: 32117226 DOI: 10.3389/fimmu.2020.00027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
75 Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Sci Transl Med 2017;9:eaal4712. [PMID: 28904226 DOI: 10.1126/scitranslmed.aal4712] [Cited by in Crossref: 97] [Cited by in F6Publishing: 92] [Article Influence: 24.3] [Reference Citation Analysis]
76 Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernández S, Mereu E, Moutinho C, Ruiz S, Lorden P, Chin VT, Kaczorowski D, Chan CL, Gallagher R, Chou A, Planas-Rigol E, Rubio-Perez C, Gut I, Piulats JM, Seoane J, Powell JE, Batlle E, Heyn H. A single-cell tumor immune atlas for precision oncology. Genome Res 2021;31:1913-26. [PMID: 34548323 DOI: 10.1101/gr.273300.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Burnett WJ, Burnett DM, Parkman G, Ramstead A, Contreras N, Gravley W, Holmen SL, Williams MA, VanBrocklin MW. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers (Basel) 2021;13:4462. [PMID: 34503272 DOI: 10.3390/cancers13174462] [Reference Citation Analysis]
78 Velaga R, Sugimoto M. Future Paradigm of Breast Cancer Resistance and Treatment. In: Prosperi JR, editor. Resistance to Targeted Therapies in Breast Cancer. Cham: Springer International Publishing; 2017. pp. 155-78. [DOI: 10.1007/978-3-319-70142-4_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
79 Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 2016;5:e1204507. [PMID: 27757299 DOI: 10.1080/2162402X.2016.1204507] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
80 Qin Q, Lauver M, Maru S, Lin E, Lukacher AE. Reducing persistent polyomavirus infection increases functionality of virus-specific memory CD8 T cells. Virology 2017;502:198-205. [PMID: 28063344 DOI: 10.1016/j.virol.2016.12.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Yarmarkovich M, Maris JM. When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. Cancer Cell 2019;36:575-6. [PMID: 31951557 DOI: 10.1016/j.ccell.2019.11.006] [Reference Citation Analysis]
82 Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol 2021;22:1034-46. [PMID: 34143970 DOI: 10.1016/S1470-2045(21)00216-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
83 Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 2019;565:43-8. [PMID: 30559380 DOI: 10.1038/s41586-018-0768-9] [Cited by in Crossref: 193] [Cited by in F6Publishing: 176] [Article Influence: 48.3] [Reference Citation Analysis]
84 Ota Y, Takahari D, Suzuki T, Osumi H, Nakayama I, Oki A, Wakatsuki T, Ichimura T, Ogura M, Shinozaki E, Suenaga M, Chin K, Yamaguchi K. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemother Pharmacol 2020;85:265-72. [PMID: 31907646 DOI: 10.1007/s00280-019-04023-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
85 Chen Z, Pang N, Du R, Zhu Y, Fan L, Cai D, Ding Y, Ding J. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells. Mediators Inflamm 2016;2016:6891482. [PMID: 27721577 DOI: 10.1155/2016/6891482] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
86 Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. Immunotherapy biomarkers 2016: overcoming the barriers. J Immunother Cancer 2017;5:29. [PMID: 28653584 DOI: 10.1186/s40425-017-0225-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
87 Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol 2016;34:556-65. [PMID: 27836246 DOI: 10.1016/j.urolonc.2016.10.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
88 Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, Vasserman AN, Zuo N, Angel LF, Gow AJ, Kang I, Wight TN, Eruslanov E, Swartz MA, Krymskaya VP. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2018;59:723-32. [PMID: 30095976 DOI: 10.1165/rcmb.2018-0123OC] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 6.3] [Reference Citation Analysis]
89 Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci Adv 2019;5:eaav2437. [PMID: 30801016 DOI: 10.1126/sciadv.aav2437] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
90 Acres B, Lacoste G, Limacher JM. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour. Curr Top Microbiol Immunol 2017;405:79-97. [PMID: 25702159 DOI: 10.1007/82_2015_429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
91 Park SH, Yoon SJ, Choi S, Kim JS, Lee MS, Lee SJ, Lee SH, Min JK, Son MY, Ryu CM, Yoo J, Park YJ. Bacterial type III effector protein HopQ inhibits melanoma motility through autophagic degradation of vimentin. Cell Death Dis 2020;11:231. [PMID: 32286254 DOI: 10.1038/s41419-020-2427-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Wang D, Wang T, Yu H, Feng B, Zhou L, Zhou F, Hou B, Zhang H, Luo M, Li Y. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci Immunol 2019;4:eaau6584. [PMID: 31300478 DOI: 10.1126/sciimmunol.aau6584] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 42.0] [Reference Citation Analysis]
93 Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 2020;37:720-734.e13. [PMID: 32359397 DOI: 10.1016/j.ccell.2020.04.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
94 Muthuswamy R, Corman JM, Dahl K, Chatta GS, Kalinski P. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells. Prostate 2016;76:1095-105. [PMID: 27199259 DOI: 10.1002/pros.23194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
95 Zhang C, Zhang S, Xu D, Liu R, Zhu Q, Zhao Y, Mao Y, Tian Y. Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis. Cancer Manag Res 2019;11:3957-69. [PMID: 31118808 DOI: 10.2147/CMAR.S202756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol 2018;36:633-41. [PMID: 29337640 DOI: 10.1200/JCO.2017.75.3384] [Cited by in Crossref: 546] [Cited by in F6Publishing: 387] [Article Influence: 136.5] [Reference Citation Analysis]
97 London NR Jr, Rooper LM, Bishop JA, Xu H, Bernhardt LJ, Ishii M, Hann CL, Taube JM, Izumchenko E, Gaykalova DA, Gallia GL. Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurg 2020;135:e187-93. [PMID: 31785431 DOI: 10.1016/j.wneu.2019.11.112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
98 Stasikowska-Kanicka O, Wągrowska-Danilewicz M, Danilewicz M. CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS 2018;126:732-8. [PMID: 30160018 DOI: 10.1111/apm.12881] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
99 Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591. [PMID: 29686284 DOI: 10.1038/s41467-018-03900-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
100 Karami Fath M, Azargoonjahromi A, Jafari N, Mehdi M, Alavi F, Daraei M, Mohammadkhani N, Mueller AL, Brockmueller A, Shakibaei M, Payandeh Z. Exosome application in tumorigenesis: diagnosis and treatment of melanoma. Med Oncol 2022;39:19. [PMID: 34982284 DOI: 10.1007/s12032-021-01621-8] [Reference Citation Analysis]
101 Nakao S, Arai Y, Tasaki M, Yamashita M, Murakami R, Kawase T, Amino N, Nakatake M, Kurosaki H, Mori M, Takeuchi M, Nakamura T. Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. Sci Transl Med 2020;12:eaax7992. [PMID: 31941828 DOI: 10.1126/scitranslmed.aax7992] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 39.0] [Reference Citation Analysis]
102 Afzal S, Gil-Farina I, Gabriel R, Ahmad S, von Kalle C, Schmidt M, Fronza R. Systematic comparative study of computational methods for T-cell receptor sequencing data analysis. Brief Bioinform 2019;20:222-34. [PMID: 29028876 DOI: 10.1093/bib/bbx111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
103 Davis RS. Roles for the FCRL6 Immunoreceptor in Tumor Immunology. Front Immunol 2020;11:575175. [PMID: 33162991 DOI: 10.3389/fimmu.2020.575175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Loo K, Daud AI. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017;23:3-9. [PMID: 28114249 DOI: 10.1097/ppo.0000000000000238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
105 Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue EH, Mog BJ, Hou W, Justesen S, Blosser R, Tam A, Anagnostou V, Cottrell TR, Guo H, Chan HY, Singh D, Thapa S, Dykema AG, Burman P, Choudhury B, Aparicio L, Cheung LS, Lanis M, Belcaid Z, El Asmar M, Illei PB, Wang R, Meyers J, Schuebel K, Gupta A, Skaist A, Wheelan S, Naidoo J, Marrone KA, Brock M, Ha J, Bush EL, Park BJ, Bott M, Jones DR, Reuss JE, Velculescu VE, Chaft JE, Kinzler KW, Zhou S, Vogelstein B, Taube JM, Hellmann MD, Brahmer JR, Merghoub T, Forde PM, Yegnasubramanian S, Ji H, Pardoll DM, Smith KN. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 2021;596:126-32. [PMID: 34290408 DOI: 10.1038/s41586-021-03752-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Saha S, Yakati V, Shankar G, Jaggarapu MMCS, Moku G, Madhusudana K, Banerjee R, Ramkrishna S, Srinivas R, Chaudhuri A. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma. J Mater Chem B 2020;8:4318-30. [PMID: 32330214 DOI: 10.1039/c9tb02700a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
107 Ali AMR, Tsai JW, Leung CH, Lin H, Ravi V, Conley AP, Lazar AJ, Wang WL, Nathenson MJ. The immune microenvironment of uterine adenosarcomas. Clin Sarcoma Res 2020;10:5. [PMID: 32231779 DOI: 10.1186/s13569-020-0127-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
108 Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.Ther Adv Med Oncol. 2019;11:1758835919862692. [PMID: 31384311 DOI: 10.1177/1758835919862692] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
109 Kaur N, Goyal A, Sindhu RK. Therapeutic Monoclonal Antibodies in Clinical Practice against Cancer. Anticancer Agents Med Chem 2020;20:1895-907. [PMID: 32619180 DOI: 10.2174/1871520620666200703191653] [Reference Citation Analysis]
110 Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22(2): 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557] [Cited by in CrossRef: 154] [Cited by in F6Publishing: 138] [Article Influence: 25.7] [Reference Citation Analysis]
111 De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, Rottey S. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. Oral Oncology 2017;70:34-42. [DOI: 10.1016/j.oraloncology.2017.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
112 Shen K, Wei Y, Lv T, Song Y, Jiang X, Lu Z, Zhan P, Wang X, Fan M, Lu W. The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC. BMC Bioinformatics 2021;22:471. [PMID: 34587898 DOI: 10.1186/s12859-021-04379-y] [Reference Citation Analysis]
113 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
114 Haanen JBAG. Converting Cold into Hot Tumors by Combining Immunotherapies. Cell. 2017;170:1055-1056. [PMID: 28886376 DOI: 10.1016/j.cell.2017.08.031] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 20.6] [Reference Citation Analysis]
115 Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:E5521. [PMID: 32752264 DOI: 10.3390/ijms21155521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, Tewari M, Thomas D, Zhao L, Brown N, Frankel TL, Warren EH, Ramnath N. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020;108:170-7. [PMID: 31756415 DOI: 10.1016/j.ijrobp.2019.10.047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
117 Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res 2019;25:3074-83. [PMID: 30635339 DOI: 10.1158/1078-0432.CCR-18-1942] [Cited by in Crossref: 201] [Cited by in F6Publishing: 133] [Article Influence: 67.0] [Reference Citation Analysis]
118 Grizzi F, Castello A, Lopci E. Is it time to change our vision of tumor metabolism prior to immunotherapy? Eur J Nucl Med Mol Imaging 2018;45:1072-5. [PMID: 29532102 DOI: 10.1007/s00259-018-3988-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
119 Xu X, Xie K, Li B, Xu L, Huang L, Feng Y, Pi C, Zhang J, Huang T, Jiang M, Gu H, Fang J. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. Int Immunopharmacol 2021;101:108199. [PMID: 34673297 DOI: 10.1016/j.intimp.2021.108199] [Reference Citation Analysis]
120 González S, Volkova N, Beer P, Gerstung M. Immuno-oncology from the perspective of somatic evolution. Semin Cancer Biol 2018;52:75-85. [PMID: 29223477 DOI: 10.1016/j.semcancer.2017.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
121 Li A, Barsoumian HB, Schoenhals JE, Cushman TR, Caetano MS, Wang X, Valdecanas DR, Niknam S, Younes AI, Li G, Woodward WA, Cortez MA, Welsh JW. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett 2018;431:54-63. [PMID: 29746927 DOI: 10.1016/j.canlet.2018.05.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
122 Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P. Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology 2018;7:e1450715. [PMID: 30221044 DOI: 10.1080/2162402X.2018.1450715] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
123 Aoki H, Ueha S, Nakamura Y, Shichino S, Nakajima H, Shimomura M, Sato A, Nakatsura T, Yoshino T, Matsushima K. Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade. Cancer Sci 2021;112:2993-3004. [PMID: 34014607 DOI: 10.1111/cas.14975] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Cavaliere A, Merz V, Casalino S, Zecchetto C, Simionato F, Salt HL, Contarelli S, Santoro R, Melisi D. Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. J Gastric Cancer 2019;19:375-92. [PMID: 31897341 DOI: 10.5230/jgc.2019.19.e39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
125 Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084-1089. [PMID: 26541606 DOI: 10.1126/science.aac4255] [Cited by in Crossref: 1472] [Cited by in F6Publishing: 1390] [Article Influence: 210.3] [Reference Citation Analysis]
126 Kametani Y, Miyamoto A, Tsuda B, Tokuda Y. B Cell Epitope-Based Vaccination Therapy. Antibodies 2015;4:225-39. [DOI: 10.3390/antib4030225] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
127 Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Front Immunol 2018;9:496. [PMID: 29593736 DOI: 10.3389/fimmu.2018.00496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
128 Ono R, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Ishikawa M, Minamoto T, Razia S, Ishikawa N, Otsuki Y, Nakayama S, Onuma H, Kurioka H, Kyo S. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). Int J Mol Sci 2019;20:E3744. [PMID: 31370215 DOI: 10.3390/ijms20153744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
129 Liang L, Ge K, Zhang F, Ge Y. The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cell Mol Biol Lett 2018;23:58. [PMID: 30564277 DOI: 10.1186/s11658-018-0122-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
130 Tietze JK, Angelova D, Heppt MV, Reinholz M, Murphy WJ, Spannagl M, Ruzicka T, Berking C. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur J Cancer 2017;75:268-79. [PMID: 28242504 DOI: 10.1016/j.ejca.2016.12.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
131 Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017;14:463-82. [PMID: 28374786 DOI: 10.1038/nrclinonc.2017.43] [Cited by in Crossref: 528] [Cited by in F6Publishing: 497] [Article Influence: 105.6] [Reference Citation Analysis]
132 Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res 2019;25:2442-9. [PMID: 30617133 DOI: 10.1158/1078-0432.CCR-18-2652] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
133 Ott PA. Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am 2019;33:249-60. [PMID: 30832998 DOI: 10.1016/j.hoc.2018.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU. Targeting tumor-associated acidity in cancer immunotherapy. Cancer Immunol Immunother 2018;67:1331-48. [PMID: 29974196 DOI: 10.1007/s00262-018-2195-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
135 Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G. Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol 2017;8:267. [PMID: 28421069 DOI: 10.3389/fimmu.2017.00267] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
136 Saeed M, Chen F, Ye J, Shi Y, Lammers T, De Geest BG, Xu ZP, Yu H. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Adv Mater 2021;33:e2008094. [PMID: 34048101 DOI: 10.1002/adma.202008094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Apavaloaei A, Hardy MP, Thibault P, Perreault C. The Origin and Immune Recognition of Tumor-Specific Antigens. Cancers (Basel) 2020;12:E2607. [PMID: 32932620 DOI: 10.3390/cancers12092607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
138 Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016;13:157-70. [PMID: 27458525 DOI: 10.20892/j.issn.2095-3941.2016.0009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
139 González-cao M, Arance A, Piulats JM, Marquez-rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-algarra S; Spanish Melanoma Group. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. Clin Transl Oncol 2017;19:761-8. [DOI: 10.1007/s12094-016-1602-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
140 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy 2016;8:907-21. [PMID: 27381685 DOI: 10.2217/imt-2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
141 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
142 Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ. Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. Cancer Res 2019;79:1113-23. [PMID: 30674537 DOI: 10.1158/0008-5472.CAN-18-1722] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
143 . Cancer Immunotherapy Scores Again. Cell 2015;160:7-9. [DOI: 10.1016/j.cell.2014.12.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
144 Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol 2017;19:796-807. [PMID: 28115578 DOI: 10.1093/neuonc/now287] [Cited by in Crossref: 45] [Cited by in F6Publishing: 70] [Article Influence: 11.3] [Reference Citation Analysis]
145 Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A 2020;117:1119-28. [PMID: 31888983 DOI: 10.1073/pnas.1904022116] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 15.7] [Reference Citation Analysis]
146 Liu J, Xu M, Yuan Z. Immunoscore Guided Cold Tumors to Acquire “Temperature” Through Integrating Physicochemical and Biological Methods. BIO Integration 2020;1:6-14. [DOI: 10.15212/bioi-2020-0002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
147 Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218. [PMID: 30610226 DOI: 10.1038/s41573-018-0007-y] [Cited by in Crossref: 655] [Cited by in F6Publishing: 653] [Article Influence: 218.3] [Reference Citation Analysis]
148 Kumar R, Thiagarajan K, Jagannathan L, Liu L, Mayawala K, de Alwis D, Topp B. Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response. CPT Pharmacometrics Syst Pharmacol 2021;10:684-95. [PMID: 33938166 DOI: 10.1002/psp4.12637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med 2019;8:E1534. [PMID: 31557787 DOI: 10.3390/jcm8101534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
150 Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 2016;76:999-1008. [PMID: 26833127 DOI: 10.1158/0008-5472.CAN-15-1439] [Cited by in Crossref: 241] [Cited by in F6Publishing: 154] [Article Influence: 40.2] [Reference Citation Analysis]
151 Yang M, Yu Q, Liu J, Fu W, Cao Y, Yu L, Shao S, Wang X, Niu H, Wang Y. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. J Surg Oncol 2015;112:430-5. [PMID: 26265374 DOI: 10.1002/jso.24012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
152 Bedhiafi T, Inchakalody VP, Fernandes Q, Mestiri S, Billa N, Uddin S, Merhi M, Dermime S. The potential role of vitamin C in empowering cancer immunotherapy. Biomed Pharmacother 2021;146:112553. [PMID: 34923342 DOI: 10.1016/j.biopha.2021.112553] [Reference Citation Analysis]
153 Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev 2020;84:101977. [PMID: 32018128 DOI: 10.1016/j.ctrv.2020.101977] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
154 Kikuchi M, Yamashita D, Hara S, Takebayashi S, Hamaguchi K, Mizuno K, Omori K, Shinohara S. Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma. Head Neck 2021;43:534-43. [PMID: 33029887 DOI: 10.1002/hed.26498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
155 Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, Mizuno T. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep 2020;10:18311. [PMID: 33110170 DOI: 10.1038/s41598-020-75533-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
156 Penaloza-MacMaster P. CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology 2017;151:146-53. [PMID: 28375543 DOI: 10.1111/imm.12739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
157 Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol 2018;129:27-39. [PMID: 30097235 DOI: 10.1016/j.critrevonc.2018.06.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
158 Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-sela G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol 2018;35. [DOI: 10.1007/s12032-018-1080-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 14.3] [Reference Citation Analysis]
159 Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS One 2016;11:e0160004. [PMID: 27467256 DOI: 10.1371/journal.pone.0160004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
160 Bence C, Hofman V, Chamorey E, Long-Mira E, Lassalle S, Albertini AF, Liolios I, Zahaf K, Picard A, Montaudié H, Lacour JP, Passeron T, Andea AA, Ilie M, Hofman P. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. J Eur Acad Dermatol Venereol 2020;34:984-94. [PMID: 31625630 DOI: 10.1111/jdv.16016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
161 Jhun I, Shepherd D, Hung YP, Madrigal E, Le LP, Mino-Kenudson M. Digital Image Analysis for Estimating Stromal CD8+ Tumor-Infiltrating Lymphocytes in Lung Adenocarcinoma. J Pathol Inform 2021;12:28. [PMID: 34447608 DOI: 10.4103/jpi.jpi_36_20] [Reference Citation Analysis]
162 Chaudhary B, Elkord E. Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) 2016;4:E28. [PMID: 27509527 DOI: 10.3390/vaccines4030028] [Cited by in Crossref: 213] [Cited by in F6Publishing: 216] [Article Influence: 35.5] [Reference Citation Analysis]
163 Yoshimura K, Inoue Y, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Sugimura H, Suda T. MET Amplification and Efficacy of Nivolumab in Patients With NSCLC. JTO Clin Res Rep 2021;2:100239. [PMID: 34766065 DOI: 10.1016/j.jtocrr.2021.100239] [Reference Citation Analysis]
164 Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 2015;6:40836-49. [PMID: 26517811 DOI: 10.18632/oncotarget.5696] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
165 Denton AE, Roberts EW, Fearon DT. Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2018;1060:99-114. [PMID: 30155624 DOI: 10.1007/978-3-319-78127-3_6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 16.7] [Reference Citation Analysis]
166 Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med 2018;10:eaan3311. [PMID: 29643229 DOI: 10.1126/scitranslmed.aan3311] [Cited by in Crossref: 110] [Cited by in F6Publishing: 108] [Article Influence: 36.7] [Reference Citation Analysis]
167 Tikoo S, Haass NK. Friends or foes: IL-10 and TGF- β in melanoma. Exp Dermatol 2015;24:254-5. [DOI: 10.1111/exd.12661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
168 Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-Garcia A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treat Rev 2017;53:79-97. [PMID: 28088073 DOI: 10.1016/j.ctrv.2016.12.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
169 Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, Sequist LV, Ramaswamy S, Miyamoto DT, Lawrence M, Toner M, Isselbacher KJ, Maheswaran S, Haber DA. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 2018;115:2467-72. [PMID: 29453278 DOI: 10.1073/pnas.1719264115] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 16.0] [Reference Citation Analysis]
170 Evans M, O'Sullivan B, Smith M, Taniere P. Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we? Transl Lung Cancer Res 2018;7:682-90. [PMID: 30505713 DOI: 10.21037/tlcr.2018.06.09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
171 Liu XS, Mardis ER. Applications of Immunogenomics to Cancer. Cell 2017;168:600-12. [PMID: 28187283 DOI: 10.1016/j.cell.2017.01.014] [Cited by in Crossref: 118] [Cited by in F6Publishing: 107] [Article Influence: 23.6] [Reference Citation Analysis]
172 Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Baba H. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer. Annals of Surgery 2019;269:471-8. [DOI: 10.1097/sla.0000000000002616] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 18.7] [Reference Citation Analysis]
173 Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerg Top Life Sci 2017;1:471-86. [PMID: 33525801 DOI: 10.1042/ETLS20170068] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
174 Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J Immunother Cancer 2019;7:325. [PMID: 31775882 DOI: 10.1186/s40425-019-0799-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
175 Jiang Y, Zhang C, Zhang J, Han D, Shi X. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. Int Immunopharmacol 2021;101:108344. [PMID: 34763233 DOI: 10.1016/j.intimp.2021.108344] [Reference Citation Analysis]
176 Lin GL, Nagaraja S, Filbin MG, Suvà ML, Vogel H, Monje M. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun 2018;6:51. [PMID: 29954445 DOI: 10.1186/s40478-018-0553-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
177 Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36. [PMID: 26288737 DOI: 10.1186/s40425-015-0078-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
178 Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 2016;18:1357-66. [PMID: 27370400 DOI: 10.1093/neuonc/now132] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
179 Möller M, Turzer S, Schütte W, Seliger B, Riemann D. Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade. J Immunother 2020;43:57-66. [PMID: 31592989 DOI: 10.1097/CJI.0000000000000297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
180 Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H, Wang J, Wen D, Zhang Y, Lu Y, Yang G, Jiang C, Wang J, Dotti G, Gu Z. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol 2019;14:89-97. [PMID: 30531990 DOI: 10.1038/s41565-018-0319-4] [Cited by in Crossref: 290] [Cited by in F6Publishing: 268] [Article Influence: 72.5] [Reference Citation Analysis]
181 Hamaidi I, Zhang L, Kim N, Wang MH, Iclozan C, Fang B, Liu M, Koomen JM, Berglund AE, Yoder SJ, Yao J, Engelman RW, Creelan BC, Conejo-Garcia JR, Antonia SJ, Mulé JJ, Kim S. Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. Cell Metab 2020;32:420-436.e12. [PMID: 32768387 DOI: 10.1016/j.cmet.2020.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
182 Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol 2017;24:235-51. [PMID: 28777142 DOI: 10.1097/PAP.0000000000000162] [Cited by in Crossref: 213] [Cited by in F6Publishing: 125] [Article Influence: 53.3] [Reference Citation Analysis]
183 Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Zimmer L, Livingstone E, Becker JC, Lodde G, Sucker A, Griewank K, Horn S, Hadaschik E, Roesch A, Schadendorf D, Engel DR, Ugurel S. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Front Oncol 2021;11:741993. [PMID: 34621681 DOI: 10.3389/fonc.2021.741993] [Reference Citation Analysis]
184 Qin SS, Han BJ, Williams A, Jackson KM, Jewell R, Chacon AC, Lord EM, Linehan DC, Kim M, Reuben A, Gerber SA, Prieto PA. Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model. Cancers (Basel) 2021;13:2293. [PMID: 34064795 DOI: 10.3390/cancers13102293] [Reference Citation Analysis]
185 Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. J Immunother Cancer 2019;7:119. [PMID: 31053174 DOI: 10.1186/s40425-019-0603-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
186 Gill DM, Sonpavde G, Pal SK, Agarwal N. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Immunotherapy 2017;9:463-6. [DOI: 10.2217/imt-2017-0033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
187 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
188 Chen B, Xie X, Lan F, Liu W. Identification of prognostic markers by weighted gene co-expression network analysis in non-small cell lung cancer. Bioengineered 2021;12:4924-35. [PMID: 34369264 DOI: 10.1080/21655979.2021.1960764] [Reference Citation Analysis]
189 Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med 2019;25:389-402. [PMID: 30842677 DOI: 10.1038/s41591-019-0382-x] [Cited by in Crossref: 154] [Cited by in F6Publishing: 142] [Article Influence: 51.3] [Reference Citation Analysis]
190 Lejeune FJ. The conquest of melanoma by immunotherapy. Melanoma Research 2015;25:373-5. [DOI: 10.1097/cmr.0000000000000178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
191 Hu X, Wu T, Qin X, Qi Y, Qiao Q, Yang C, Zhang Z. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy. Adv Healthcare Mater 2019;8:1800837. [DOI: 10.1002/adhm.201800837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
192 Shi R, Tang Y, Miao H. Metabolism in tumor microenvironment: Implications for cancer immunotherapy. MedComm 2020;1:47-68. [DOI: 10.1002/mco2.6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
193 Grassi F, De Ponte Conti B. The P2X7 Receptor in Tumor Immunity. Front Cell Dev Biol 2021;9:694831. [PMID: 34239877 DOI: 10.3389/fcell.2021.694831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Casas-Solís J, Huizar-López MDR, Irecta-Nájera CA, Pita-López ML, Santerre A. Immunomodulatory Effect of Lactobacillus casei in a Murine Model of Colon Carcinogenesis. Probiotics Antimicrob Proteins 2020;12:1012-24. [PMID: 31797281 DOI: 10.1007/s12602-019-09611-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
195 [DOI: 10.1101/2020.08.09.20170910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6:4. [PMID: 29368638 DOI: 10.1186/s40425-018-0314-1] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 18.8] [Reference Citation Analysis]
197 Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining response. Adv Radiat Oncol 2018;3:534-47. [PMID: 30370353 DOI: 10.1016/j.adro.2018.07.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
198 Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I, Grynszpan L, Gros G, de Montpréville V, Planchard D, Théret N, Besse B, Mami-Chouaib F. Integrin-αV-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun 2021;12:5209. [PMID: 34471106 DOI: 10.1038/s41467-021-25322-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Vassilev L, Ranki T, Joensuu T, Jäger E, Karbach J, Wahle C, Partanen K, Kairemo K, Alanko T, Turkki R, Linder N, Lundin J, Ristimäki A, Kankainen M, Hemminki A, Backman C, Dienel K, von Euler M, Haavisto E, Hakonen T, Juhila J, Jäderberg M, Priha P, Vuolanto A, Pesonen S. Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. Oncoimmunology 2015;4:e1017702. [PMID: 26140248 DOI: 10.1080/2162402X.2015.1017702] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
200 Golshani G, Zhang Y. Advances in immunotherapy for colorectal cancer: a review. Therap Adv Gastroenterol 2020;13:1756284820917527. [PMID: 32536977 DOI: 10.1177/1756284820917527] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
201 Guerrera F, Tabbò F, Ruffini E, Bertoglio P. Changing paradigms of non-small cell lung cancer treatment. J Thorac Dis 2018;10:S4170-2. [PMID: 30631585 DOI: 10.21037/jtd.2018.11.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
202 Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, Stec M, Siedlar M, Holak TA, Plewka J. CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not? Molecules 2019;24:E2804. [PMID: 31374878 DOI: 10.3390/molecules24152804] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 17.0] [Reference Citation Analysis]
203 Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. Immunotherapy advances in uro-genital malignancies. Crit Rev Oncol Hematol 2016;105:52-64. [PMID: 27372200 DOI: 10.1016/j.critrevonc.2016.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
204 Bahmani B, Gong H, Luk BT, Haushalter KJ, DeTeresa E, Previti M, Zhou J, Gao W, Bui JD, Zhang L, Fang RH, Zhang J. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors. Nat Commun 2021;12:1999. [PMID: 33790276 DOI: 10.1038/s41467-021-22311-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
205 Allen PB, Gordon LI. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. Expert Rev Hematol 2016;9:939-49. [PMID: 27622603 DOI: 10.1080/17474086.2016.1235970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
206 Rivera-Colon G, Chen H, Molberg K, Niu S, Strickland AL, Castrillon DH, Carrick K, Gwin K, Lea J, Zheng W, Lucas E. PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes. Am J Surg Pathol 2021;45:742-52. [PMID: 33298732 DOI: 10.1097/PAS.0000000000001633] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res 2017;5:12. [PMID: 28331612 DOI: 10.1186/s40364-017-0093-8] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 21.6] [Reference Citation Analysis]
208 Kursunel MA, Esendagli G. The untold story of IFN-γ in cancer biology. Cytokine & Growth Factor Reviews 2016;31:73-81. [DOI: 10.1016/j.cytogfr.2016.07.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 7.5] [Reference Citation Analysis]
209 Meng F, Su Y, Xu B. Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer. Mol Oncol 2020;14:2701-12. [PMID: 32941674 DOI: 10.1002/1878-0261.12804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
210 Meng X, Gao Y, Yang L, Jing H, Teng F, Huang Z, Xing L. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Clin Lung Cancer 2019;20:48-58. [PMID: 30341017 DOI: 10.1016/j.cllc.2018.09.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
211 Tomela K, Pietrzak B, Schmidt M, Mackiewicz A. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life (Basel) 2020;10:E219. [PMID: 32992737 DOI: 10.3390/life10100219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
212 Alessi JV, Ricciuti B, Alden SL, Bertram AA, Lin JJ, Sakhi M, Nishino M, Vaz VR, Lindsay J, Turner MM, Pfaff K, Sharma B, Felt KD, Rodig SJ, Gainor JF, Awad MM. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer 2021;9:e003536. [PMID: 34824161 DOI: 10.1136/jitc-2021-003536] [Reference Citation Analysis]
213 Yang Y, Pang Z, Ding N, Dong W, Ma W, Li Y, Du J, Liu Q. The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis. Oncotarget 2016;7:74350-61. [PMID: 27542277 DOI: 10.18632/oncotarget.11291] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
214 Kapoor SS, Zaiss DMW. Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment. Biomedicines 2022;10:52. [DOI: 10.3390/biomedicines10010052] [Reference Citation Analysis]
215 Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2016;100:88-98. [PMID: 26895815 DOI: 10.1016/j.critrevonc.2016.02.001] [Cited by in Crossref: 200] [Cited by in F6Publishing: 197] [Article Influence: 33.3] [Reference Citation Analysis]
216 Johansson-percival A, He B, Ganss R. Immunomodulation of Tumor Vessels: It Takes Two to Tango. Trends in Immunology 2018;39:801-14. [DOI: 10.1016/j.it.2018.08.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
217 Griewank KG. Biomarkers in melanoma. Scandinavian Journal of Clinical and Laboratory Investigation 2016;76:S104-12. [DOI: 10.1080/00365513.2016.1210336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
218 Wu Y, Biswas D, Swanton C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Semin Cancer Biol 2021:S1044-579X(21)00042-0. [PMID: 33631295 DOI: 10.1016/j.semcancer.2021.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. J Thorac Oncol 2018;13:521-32. [PMID: 29269008 DOI: 10.1016/j.jtho.2017.11.132] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 10.4] [Reference Citation Analysis]
220 Wu ZY, He YQ, Wang TM, Yang DW, Li DH, Deng CM, Cao LJ, Zhang JB, Xue WQ, Jia WH. Glycogenes in Oncofetal Chondroitin Sulfate Biosynthesis are Differently Expressed and Correlated With Immune Response in Placenta and Colorectal Cancer. Front Cell Dev Biol 2021;9:763875. [PMID: 34966741 DOI: 10.3389/fcell.2021.763875] [Reference Citation Analysis]
221 Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, Ataullakhanov R, Miheecheva N, Frenkel F, Wang Y, Zhang M, Hawke D, Han L, Zhou S, Zhang Y, Wang Z, Decker WK, Sonnemann HM, Roszik J, Forget MA, Davies MA, Bernatchez C, Yee C, Bassett R, Hwu P, Du X, Lizee G. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021;9:e002531. [PMID: 34244308 DOI: 10.1136/jitc-2021-002531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
222 Huang W, He L, Ouyang J, Chen Q, Liu C, Tao W, Chen T. Triangle-Shaped Tellurium Nanostars Potentiate Radiotherapy by Boosting Checkpoint Blockade Immunotherapy. Matter 2020;3:1725-53. [DOI: 10.1016/j.matt.2020.08.027] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
223 Li L, Wang J, Radford DC, Kopeček J, Yang J. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer. J Control Release 2021;332:652-9. [PMID: 33607175 DOI: 10.1016/j.jconrel.2021.02.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Sandler JE, Kaumaya M, Halmos B. Biomarker use in lung cancer management: expanding horizons. Biomark Med 2018;12:315-20. [PMID: 29569465 DOI: 10.2217/bmm-2018-0028] [Reference Citation Analysis]
225 Zhou B, Jiang Q, Xiao X, Xu X, Xu Y, Kong Y, Zhang W, Zeng Y, Liu X, Luo B. Assisting anti-PD-1 antibody treatment with a liposomal system capable of recruiting immune cells. Nanoscale 2019;11:7996-8011. [PMID: 30969294 DOI: 10.1039/c9nr01434a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
226 Meti N, Esfahani K, Johnson NA. The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. Cancers (Basel) 2018;10:E204. [PMID: 29914088 DOI: 10.3390/cancers10060204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
227 Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 2021;6:eabi8800. [PMID: 34714687 DOI: 10.1126/sciimmunol.abi8800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Tej GNVC, Neogi K, Nayak PK. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody. Int Immunopharmacol 2019;77:106002. [PMID: 31711939 DOI: 10.1016/j.intimp.2019.106002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
229 de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 2018;10:eaar5894. [PMID: 29743350 DOI: 10.1126/scitranslmed.aar5894] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
230 Akabane H, Sullivan RJ. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. Am J Clin Dermatol 2016;17:1-10. [DOI: 10.1007/s40257-015-0159-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
231 Xu Y, Li J, Tong B, Chen M, Liu X, Zhong W, Zhao J, Wang M. Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. ESMO Open 2020;5:e000823. [PMID: 32830120 DOI: 10.1136/esmoopen-2020-000823] [Reference Citation Analysis]
232 Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther 2018;26:2553-66. [PMID: 30217730 DOI: 10.1016/j.ymthe.2018.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
233 Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood 2021;137:216-31. [PMID: 33024998 DOI: 10.1182/blood.2020006073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
234 Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Ann Transl Med 2020;8:1095. [PMID: 33145314 DOI: 10.21037/atm-20-3735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
235 Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res 2016;4:845-57. [PMID: 27589875 DOI: 10.1158/2326-6066.CIR-16-0060] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
236 Fenwick C, Loredo-Varela JL, Joo V, Pellaton C, Farina A, Rajah N, Esteves-Leuenberger L, Decaillon T, Suffiotti M, Noto A, Ohmiti K, Gottardo R, Weissenhorn W, Pantaleo G. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med 2019;216:1525-41. [PMID: 31123083 DOI: 10.1084/jem.20182359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
237 Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields CE, Niknafs N, Yen RC, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Anagnostou V, Strissel PL, Strick R, Velculescu VE, Baylin SB. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell 2017;171:1284-1300.e21. [PMID: 29195073 DOI: 10.1016/j.cell.2017.10.022] [Cited by in Crossref: 157] [Cited by in F6Publishing: 152] [Article Influence: 31.4] [Reference Citation Analysis]
238 Liang F, Xu Y, Chen Y, Zhong H, Wang Z, Nong T, Zhong J. Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma. Front Mol Biosci 2021;8:673918. [PMID: 35004839 DOI: 10.3389/fmolb.2021.673918] [Reference Citation Analysis]
239 Campesato LF, Silva APM, Cordeiro L, Correa BR, Navarro FCP, Zanin RF, Marçola M, Inoue LT, Duarte ML, Molgora M, Pasqualini F, Massara M, Galante P, Barroso-Sousa R, Polentarutti N, Riva F, Costa ET, Mantovani A, Garlanda C, Camargo AA. High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. Oncotarget 2017;8:49470-83. [PMID: 28533483 DOI: 10.18632/oncotarget.17713] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
240 Pfannenstiel LW, McNeilly C, Xiang C, Kang K, Diaz-Montero CM, Yu JS, Gastman BR. Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 2019;8:e1507669. [PMID: 30546944 DOI: 10.1080/2162402X.2018.1507669] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
241 [DOI: 10.1101/675926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Juco J, Parra ER, Rebelatto MC, Rimm DL, Rodriguez-Canales J, Schalper KA, Stack EC, Ferreira CS, Korski K, Lako A, Rodig SJ, Schenck E, Steele KE, Surace MJ, Tetzlaff MT, von Loga K, Wistuba II, Bifulco CB; Society for Immunotherapy of Cancer (SITC) Pathology Task Force. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer 2020;8:e000155. [PMID: 32414858 DOI: 10.1136/jitc-2019-000155] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
243 Pistillo MP, Carosio R, Grillo F, Fontana V, Mastracci L, Morabito A, Banelli B, Tanda E, Cecchi F, Dozin B, Gualco M, Salvi S, Spagnolo F, Poggi A, Queirolo P. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. Clin Immunol 2020;215:108428. [PMID: 32344017 DOI: 10.1016/j.clim.2020.108428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
244 Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the Cancer-Immunity Cycle. Front Immunol 2019;10:774. [PMID: 31031765 DOI: 10.3389/fimmu.2019.00774] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
245 Sudmeier L, Tian S, Higgins KA. Multidisciplinary Management of Brain Metastases from Non-Small Cell Lung Cancer in the Era of Immunotherapy. Curr Treat Options Oncol 2021;22:77. [PMID: 34213649 DOI: 10.1007/s11864-021-00871-y] [Reference Citation Analysis]
246 Daud A. Current and Emerging Perspectives on Immunotherapy for Melanoma. Seminars in Oncology 2015;42:S3-S11. [DOI: 10.1053/j.seminoncol.2015.10.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
247 Echarti A, Hecht M, Büttner-Herold M, Haderlein M, Hartmann A, Fietkau R, Distel L. CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer. Cancers (Basel) 2019;11:E1398. [PMID: 31546872 DOI: 10.3390/cancers11091398] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
248 Obeid JM, Wages NA, Hu Y, Deacon DH, Slingluff CL Jr. Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunol Immunother 2017;66:33-43. [PMID: 27770170 DOI: 10.1007/s00262-016-1908-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
249 Pilla L, Ferrone S, Maccalli C. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther 2018;18:765-84. [PMID: 29874943 DOI: 10.1080/14712598.2018.1485649] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
250 Machiels JH, Coulie PG. The promise of immunostimulatory antibodies in head and neck cancer. Lancet Oncol 2016;17:856-7. [PMID: 27247227 DOI: 10.1016/S1470-2045(16)30106-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
251 Li X, Wang X, Ito A, Tsuji NM. A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. Nat Commun 2020;11:3858. [PMID: 32737343 DOI: 10.1038/s41467-020-17637-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
252 Hiniker SM, Maecker HT, Knox SJ. Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol. 2015;4:339-345. [PMID: 26709361 DOI: 10.1007/s13566-015-0219-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
253 Ko JS. The Immunology of Melanoma. Clin Lab Med 2017;37:449-71. [PMID: 28802495 DOI: 10.1016/j.cll.2017.06.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
254 Yang H, Wang Y, Jia Z, Wang Y, Yang X, Wu P, Song Y, Xu H, Gu D, Chen R, Xia X, Bing Z, Gao C, Cao L, Li S, Cao Z, Liang N. Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Front Oncol 2021;11:537735. [PMID: 33777727 DOI: 10.3389/fonc.2021.537735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Ceci C, Atzori MG, Lacal PM, Graziani G. Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers (Basel) 2020;12:E3401. [PMID: 33212945 DOI: 10.3390/cancers12113401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
256 Mao S, Li Y, Lu Z, Che Y, Huang J, Lei Y, Wang Y, Wang X, Liu C, Zheng S, Li N, Li J, Sun N, He J. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cell Oncol (Dordr) 2020;43:681-94. [PMID: 32462608 DOI: 10.1007/s13402-020-00515-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
257 Wang M, Ma X, Guo L, Xia F. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther 2017;11:2851-60. [PMID: 29033546 DOI: 10.2147/DDDT.S146286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
258 Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro Oncol 2020;22:773-84. [PMID: 32055852 DOI: 10.1093/neuonc/noaa036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
259 Hu G, Tu W, Yang L, Peng G, Yang L. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer Lett 2020;473:148-55. [PMID: 31911080 DOI: 10.1016/j.canlet.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
260 Taleb M, Atabakhshi-Kashi M, Wang Y, Rezvani Alanagh H, Farhadi Sabet Z, Li F, Cheng K, Li C, Qi Y, Nie G, Ying Z. Bifunctional Therapeutic Peptide Assembled Nanoparticles Exerting Improved Activities of Tumor Vessel Normalization and Immune Checkpoint Inhibition. Adv Healthc Mater 2021;10:e2100051. [PMID: 34021735 DOI: 10.1002/adhm.202100051] [Reference Citation Analysis]
261 Tang J, Jiang W, Liu D, Luo J, Wu X, Pan Z, Ding P, Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018;7:e1488566. [PMID: 30288357 DOI: 10.1080/2162402x.2018.1488566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
262 Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [PMID: 30409774 DOI: 10.1136/bmj.k4226] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 31.0] [Reference Citation Analysis]
263 Colton M, Cheadle EJ, Honeychurch J, Illidge TM. Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. Radiat Oncol 2020;15:254. [PMID: 33148287 DOI: 10.1186/s13014-020-01678-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
264 Kockx MM, McCleland M, Koeppen H. Microenvironmental regulation of tumour immunity and response to immunotherapy. J Pathol 2021;254:374-83. [PMID: 33846997 DOI: 10.1002/path.5681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
265 Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. Immunol Cell Biol. 2017;95:356-363. [PMID: 28003642 DOI: 10.1038/icb.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 86] [Article Influence: 15.0] [Reference Citation Analysis]
266 Zhang Z, Wang Y, Shan Y, Zhou R, Yin W. Oroxylin A alleviates immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15. Sci Rep 2020;10:19272. [PMID: 33159144 DOI: 10.1038/s41598-020-76285-x] [Reference Citation Analysis]
267 Lote H, Cafferkey C, Chau I. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat Rev. 2015;41:893-903. [PMID: 26412280 DOI: 10.1016/j.ctrv.2015.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
268 Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open 2021;6:100046. [PMID: 33508733 DOI: 10.1016/j.esmoop.2020.100046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
270 Park JH, Chun SH, Lee YG, Chang H, Lee KW, Kim HR, Shin SH, An HJ, Lee KE, Hwang IG, Ahn MJ, Kim SB, Keam B. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. J Cancer Res Clin Oncol 2020;146:3359-69. [PMID: 32671504 DOI: 10.1007/s00432-020-03316-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
272 An YS, Kim SH, Roh TH, Park SH, Kim TG, Kim JH. Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. Front Oncol 2021;11:618705. [PMID: 34249674 DOI: 10.3389/fonc.2021.618705] [Reference Citation Analysis]
273 Nam J, Son S, Park KS, Zou W, Shea LD, Moon JJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater 2019;4:398-414. [DOI: 10.1038/s41578-019-0108-1] [Cited by in Crossref: 261] [Cited by in F6Publishing: 147] [Article Influence: 87.0] [Reference Citation Analysis]
274 Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peeper DS, Long GV, Schumacher TNM, Blank CU. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer 2020;8:e001501. [PMID: 33262254 DOI: 10.1136/jitc-2020-001501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
275 Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, Champhekar A, Medina E, Torrejon DY, Shin DS, Tran P, Kim YJ, Puig-Saus C, Campbell K, Vega-Crespo A, Quist M, Martignier C, Luke JJ, Wolchok JD, Johnson DB, Chmielowski B, Hodi FS, Bhatia S, Sharfman W, Urba WJ, Slingluff CL Jr, Diab A, Haanen JBAG, Algarra SM, Pardoll DM, Anagnostou V, Topalian SL, Velculescu VE, Speiser DE, Kalbasi A, Ribas A. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell 2020;38:500-515.e3. [PMID: 32916126 DOI: 10.1016/j.ccell.2020.08.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
276 Dorta-Estremera S, Chin RL, Sierra G, Nicholas C, Yanamandra AV, Nookala SMK, Yang G, Singh S, Curran MA, Sastry KJ. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers. Cancer Res 2018;78:5327-39. [PMID: 30054333 DOI: 10.1158/0008-5472.CAN-18-0892] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
277 Wu Q, Wang Q, Tang X, Xu R, Zhang L, Chen X, Xue Q, Wang Z, Shi R, Wang F, Ju F, Zhang B, Zhou YL. Correlation between patients' age and cancer immunotherapy efficacy. Oncoimmunology 2019;8:e1568810. [PMID: 30906662 DOI: 10.1080/2162402X.2019.1568810] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
278 Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov 2017;7:264-76. [PMID: 28031159 DOI: 10.1158/2159-8290.CD-16-0828] [Cited by in Crossref: 402] [Cited by in F6Publishing: 278] [Article Influence: 67.0] [Reference Citation Analysis]
279 Buyse M, Saad ED, Burzykowski T, Péron J. Assessing Treatment Benefit in Immuno-oncology. Stat Biosci 2020;12:83-103. [DOI: 10.1007/s12561-020-09268-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
280 Lou X, Wang JJ, Wei YQ, He YJ, Jiang ZJ, Sun JJ. Identification of molecular heterogeneity of hepatocellular carcinoma based on immune gene expression signatures. Med Oncol 2021;38:50. [PMID: 33786682 DOI: 10.1007/s12032-021-01499-6] [Reference Citation Analysis]
281 Wang L, Hu Y, Wang S, Shen J, Wang X. Biomarkers of immunotherapy in non-small cell lung cancer. Oncol Lett 2020;20:139. [PMID: 32934707 DOI: 10.3892/ol.2020.11999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
283 Saw PE, Song EW. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell 2019;10:787-807. [PMID: 31140150 DOI: 10.1007/s13238-019-0639-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
284 Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 2020;11:1839. [PMID: 32296058 DOI: 10.1038/s41467-020-15538-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
285 Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med 2017;214:381-400. [PMID: 28115575 DOI: 10.1084/jem.20160485] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 18.0] [Reference Citation Analysis]
286 Pestana RC, Becnel M, Rubin ML, Torman DK, Crespo J, Phan J, Hanna E, Bell D, Glisson BS, Johnson JM, Lee JJ, Ferrarotto R. Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology 2020;101:104523. [DOI: 10.1016/j.oraloncology.2019.104523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
287 Kumar R, Yu F, Zhen YH, Li B, Wang J, Yang Y, Ge HX, Hu PS, Xiu J. PD-1 blockade restores impaired function of ex vivo expanded CD8+ T cells and enhances apoptosis in mismatch repair deficient EpCAM+PD-L1+ cancer cells. Onco Targets Ther 2017;10:3453-65. [PMID: 28761354 DOI: 10.2147/OTT.S130131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
288 Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 2018;11:475-86. [PMID: 29641940 DOI: 10.1080/17512433.2018.1464388] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
289 Stoltzfus CR, Sivakumar R, Kunz L, Olin Pope BE, Menietti E, Speziale D, Adelfio R, Bacac M, Colombetti S, Perro M, Gerner MY. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity. Front Immunol 2021;12:726492. [PMID: 34421928 DOI: 10.3389/fimmu.2021.726492] [Reference Citation Analysis]
290 Salema V, Fernández LÁ. Escherichia coli surface display for the selection of nanobodies. Microb Biotechnol 2017;10:1468-84. [PMID: 28772027 DOI: 10.1111/1751-7915.12819] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
291 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
292 Gelsomino F, Di Federico A, Filippini DM, Dall'Olio FG, Lamberti G, Sperandi F, Balacchi C, Brocchi S, Ardizzoni A. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report. Clin Lung Cancer 2020;21:e45-8. [PMID: 31902695 DOI: 10.1016/j.cllc.2019.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
293 Minervina A, Pogorelyy M, Mamedov I. T‐cell receptor and B‐cell receptor repertoire profiling in adaptive immunity. Transpl Int 2019;32:1111-23. [DOI: 10.1111/tri.13475] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
294 Berger G, Marloye M, Lawler SE. Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. Trends Mol Med 2019;25:412-27. [PMID: 30885429 DOI: 10.1016/j.molmed.2019.02.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
295 Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med 2020;1:100163. [PMID: 33377134 DOI: 10.1016/j.xcrm.2020.100163] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
296 Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, Lam SZ, Zhou JJ, Lannin DR, Herbst RS, Chen S. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell 2019;178:1189-1204.e23. [PMID: 31442407 DOI: 10.1016/j.cell.2019.07.044] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
297 Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL. An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE). J Immunother Cancer 2019;7:72. [PMID: 30867072 DOI: 10.1186/s40425-019-0541-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
298 Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 2018;18:1082. [PMID: 30409126 DOI: 10.1186/s12885-018-4990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
299 Peng TR, Tsai FP, Wu TW. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. Int Immunopharmacol 2017;49:85-94. [PMID: 28554108 DOI: 10.1016/j.intimp.2017.05.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
300 Karoon Kiani F, Izadi S, Ansari Dezfouli E, Ebrahimi F, Mohammadi M, Chalajour H, Mortazavi Bulus M, Nasr Esfahani M, Karpisheh V, Mahmoud Salehi Khesht A, Abbaszadeh-Goudarzi K, Soleimani A, Gholizadeh Navashenaq J, Ahmadi M, Hassannia H, Hojjat-Farsangi M, Shahmohammadi Farid S, Hashemi V, Jadidi-Niaragh F. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sci 2022;288:120166. [PMID: 34813798 DOI: 10.1016/j.lfs.2021.120166] [Reference Citation Analysis]
301 Yeo KP, Angeli V. Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Front Immunol 2017;8:83. [PMID: 28220121 DOI: 10.3389/fimmu.2017.00083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
302 Glaire MA, Brown M, Church DN, Tomlinson I. Cancer predisposition syndromes: lessons for truly precision medicine: Cancer predisposition syndromes: lessons for truly precision medicine. J Pathol 2017;241:226-35. [DOI: 10.1002/path.4842] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
303 Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 2018;362:k3529. [PMID: 30201790 DOI: 10.1136/bmj.k3529] [Cited by in Crossref: 154] [Cited by in F6Publishing: 153] [Article Influence: 38.5] [Reference Citation Analysis]
304 Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 2018;102:157-62. [DOI: 10.1111/ejh.13187] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
305 Ghavimi S, Apfel T, Azimi H, Persaud A, Pyrsopoulos NT. Management and Treatment of Hepatocellular Carcinoma with Immunotherapy: A Review of Current and Future Options. J Clin Transl Hepatol. 2020;8:168-176. [PMID: 32832397 DOI: 10.14218/jcth.2020.00001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
306 Deng B, Park JH, Ren L, Yew PY, Kiyotani K, Antic T, O'Connor K, O'Donnell PH, Nakamura Y. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken) 2018;1:e1002. [PMID: 32729250 DOI: 10.1002/cnr2.1002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
307 Zhang J, Li Y, Yang S, Zhang L, Wang W. Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. J Bone Oncol 2019;17:100245. [PMID: 31293882 DOI: 10.1016/j.jbo.2019.100245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
308 Yuan H, Nishikori M, Otsuka Y, Arima H, Kitawaki T, Takaori-Kondo A. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. Cancer Sci 2021;112:4604-16. [PMID: 34449935 DOI: 10.1111/cas.15122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Brunekreeft KL, Paijens ST, Wouters MCA, Komdeur FL, Eggink FA, Lubbers JM, Workel HH, Van Der Slikke EC, Pröpper NEJ, Leffers N, Adam J, Pijper H, Plat A, Kol A, Nijman HW, De Bruyn M. Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology 2020;9:1760705. [PMID: 32923120 DOI: 10.1080/2162402X.2020.1760705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 2020;11:2135. [PMID: 32358509 DOI: 10.1038/s41467-020-15959-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
311 Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer 2018;6:65. [PMID: 29970158 DOI: 10.1186/s40425-018-0376-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 13.5] [Reference Citation Analysis]
312 Qiu Z, Du Y. Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis. J Gastrointest Oncol 2021;12:112-20. [PMID: 33708429 DOI: 10.21037/jgo-20-568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Lattanzi M, Deng FM, Chiriboga LA, Femia AN, Meehan SA, Iyer G, Voss MH, Sundatova Y, Huang WC, Balar AV. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. J Immunother Cancer 2018;6:97. [PMID: 30285856 DOI: 10.1186/s40425-018-0415-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
314 Li J, Dong C. Nobel goes to immune checkpoint-Innovative cancer treatment by immunotherapy. Sci China Life Sci 2018;61:1445-50. [PMID: 30377902 DOI: 10.1007/s11427-018-9409-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
315 Inamura K. Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers (Basel) 2018;10:E72. [PMID: 29538329 DOI: 10.3390/cancers10030072] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
316 Dill EA, Dillon PM, Bullock TN, Mills AM. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Mod Pathol. 2018;31:1513-1522. [PMID: 29802358 DOI: 10.1038/s41379-018-0061-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
317 Mori T, Tanaka H, Suzuki S, Deguchi S, Yamakoshi Y, Yoshii M, Miki Y, Tamura T, Toyokawa T, Lee S, Muguruma K, Wanibuchi H, Ohira M. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Cancer Sci 2021;112:1746-57. [PMID: 33735485 DOI: 10.1111/cas.14888] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
318 Wu AM, Pandit-Taskar N. ImmunoPET: harnessing antibodies for imaging immune cells. Mol Imaging Biol 2021. [PMID: 34550529 DOI: 10.1007/s11307-021-01652-7] [Reference Citation Analysis]
319 Harder N, Schönmeyer R, Nekolla K, Meier A, Brieu N, Vanegas C, Madonna G, Capone M, Botti G, Ascierto PA, Schmidt G. Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. Sci Rep 2019;9:7449. [PMID: 31092853 DOI: 10.1038/s41598-019-43525-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
320 Bloom AC, Bender LH, Tiwary S, Pasquet L, Clark K, Jiang T, Xia Z, Morales-Kastresana A, Jones JC, Walters I, Terabe M, Berzofsky JA. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncoimmunology 2019;8:e1625687. [PMID: 31646070 DOI: 10.1080/2162402X.2019.1625687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
321 Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 2019;16:123-35. [DOI: 10.1038/s41571-018-0119-7] [Cited by in Crossref: 97] [Cited by in F6Publishing: 94] [Article Influence: 24.3] [Reference Citation Analysis]
322 Outh-gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C. Actualités sur l’immunothérapie en pathologie des voies aérodigestives supérieures. Annales de Pathologie 2017;37:79-89. [DOI: 10.1016/j.annpat.2016.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
323 Robert C. Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. Trends in Molecular Medicine 2017;23:983-5. [DOI: 10.1016/j.molmed.2017.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
324 Huang KW, Lee PH, Kusano T, Reccia I, Jayant K, Habib N. Impact of cavitron ultrasonic surgical aspirator (CUSA) and bipolar radiofrequency device (Habib-4X) based hepatectomy for hepatocellular carcinoma on tumour recurrence and disease-free survival. Oncotarget 2017;8:93644-54. [PMID: 29212179 DOI: 10.18632/oncotarget.21271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
325 Zhang X, Cheng C, Hou J, Qi X, Wang X, Han P, Yang X. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells. Cell Mol Immunol 2019;16:392-400. [PMID: 29568117 DOI: 10.1038/s41423-018-0021-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
326 Bozzetti C, Squadrilli A, Nizzoli R, Lagrasta C, Gasparro D, Majori M, Filippo M, Becchi G, Azzoni C, Campanini N, Pedrazzi G, Zavani A, Silini EM, Tiseo M, Gnetti L. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer. Immunotherapy 2020;12:183-93. [PMID: 32066299 DOI: 10.2217/imt-2019-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
327 Anami T, Komohara Y, Miura Y, Yamanaka K, Kurahashi R, Segawa T, Motoshima T, Murakami Y, Yatsuda J, Yamaguchi T, Sugiyama Y, Jinnouchi Y, Kamba T. High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer. Med Mol Morphol 2021. [PMID: 34136945 DOI: 10.1007/s00795-021-00292-8] [Reference Citation Analysis]
328 Surace M, Rognoni L, Rodriguez-Canales J, Steele KE. Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images. Methods Enzymol 2020;635:33-50. [PMID: 32122552 DOI: 10.1016/bs.mie.2019.07.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
329 Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D. CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients. JCI Insight 2018;3:96793. [PMID: 29997292 DOI: 10.1172/jci.insight.96793] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
330 Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835-2840. [PMID: 27903604 DOI: 10.1084/jem.20161462] [Cited by in Crossref: 150] [Cited by in F6Publishing: 148] [Article Influence: 25.0] [Reference Citation Analysis]
331 Nwani NG, Sima LE, Nieves-Neira W, Matei D. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers (Basel) 2018;10:E266. [PMID: 30103384 DOI: 10.3390/cancers10080266] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
332 Guo Y, Jin Y, Wang B, Liu B. Molecular Mechanism of Small-Molecule Inhibitors in Blocking the PD-1/PD-L1 Pathway through PD-L1 Dimerization. Int J Mol Sci 2021;22:4766. [PMID: 33946261 DOI: 10.3390/ijms22094766] [Reference Citation Analysis]
333 Delmas D, Hermetet F, Aires V. PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. Cancers (Basel) 2021;13:4509. [PMID: 34572736 DOI: 10.3390/cancers13184509] [Reference Citation Analysis]
334 Cheng S, Zhong W, Xia K, Hong P, Lin R, Wang B, Li X, Chen J, Liu Z, Zhang H, Liu C, Ye L, Ma L, Lin T, Li X, Huang J, Zhou L. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study). Oncoimmunology 2021;10:1861737. [PMID: 33489471 DOI: 10.1080/2162402X.2020.1861737] [Reference Citation Analysis]
335 Ren E, Liu C, Lv P, Wang J, Liu G. Genetically Engineered Cellular Membrane Vesicles as Tailorable Shells for Therapeutics. Adv Sci (Weinh) 2021;8:e2100460. [PMID: 34494387 DOI: 10.1002/advs.202100460] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
336 Anderson PM. Immune Therapy for Sarcomas. Adv Exp Med Biol 2017;995:127-40. [PMID: 28321815 DOI: 10.1007/978-3-319-53156-4_6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
337 Xue L, Wu P, Zhao X, Jin X, Wang J, Shi Y, Yang X, She Y, Li Y, Li C. Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma. Int J Gen Med 2021;14:6463-75. [PMID: 34675614 DOI: 10.2147/IJGM.S335266] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Zhou Q, Yan X, Liu W, Yin W, Xu H, Cheng D, Jiang X, Ren C. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis. Front Oncol 2020;10:586019. [PMID: 33425739 DOI: 10.3389/fonc.2020.586019] [Reference Citation Analysis]
339 Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, Chackerian A. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest 2018;128:644-54. [PMID: 29337311 DOI: 10.1172/JCI94586] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 12.8] [Reference Citation Analysis]
340 Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, McKee T, Dutoit V, Dietrich PY. First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology 2017;6:e1338235. [PMID: 28919999 DOI: 10.1080/2162402X.2017.1338235] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
341 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
342 Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform 2021;22:bbaa176. [PMID: 32814346 DOI: 10.1093/bib/bbaa176] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
343 Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, Kay NE, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J 2021;11:86. [PMID: 33972504 DOI: 10.1038/s41408-021-00477-5] [Reference Citation Analysis]
344 Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016;34:4102-9. [PMID: 27863197 DOI: 10.1200/JCO.2016.67.2477] [Cited by in Crossref: 347] [Cited by in F6Publishing: 200] [Article Influence: 57.8] [Reference Citation Analysis]
345 Takeda K, Kitaura K, Suzuki R, Owada Y, Muto S, Okabe N, Hasegawa T, Osugi J, Hoshino M, Tsunoda T, Okumura K, Suzuki H. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination. Cancer Immunol Immunother 2018;67:949-64. [DOI: 10.1007/s00262-018-2152-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
346 Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expr 2020;20:53-65. [PMID: 32340652 DOI: 10.3727/105221620X15880179864121] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
347 Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, Blackman S, Blanc P, Capdeville R, Caron H, Cole PD, Jiménez JC, Demolis P, Donoghue M, Elgadi M, Gajewski T, Galluzzo S, Ilaria R Jr, Jenkner A, Karres D, Kieran M, Ligas F, Lowy I, Meyers M, Oprea C, Peddareddigari VGR, Sterba J, Stockman PK, Suenaert P, Tabori U, van Tilburg C, Yancey T, Weigel B, Norga K, Reaman G, Vassal G. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. Eur J Cancer 2020;127:52-66. [PMID: 31986450 DOI: 10.1016/j.ejca.2019.12.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
348 Mardiana S, Solomon BJ, Darcy PK, Beavis PA. Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Sci Transl Med 2019;11:eaaw2293. [DOI: 10.1126/scitranslmed.aaw2293] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 20.0] [Reference Citation Analysis]
349 Nishikawa D, Suzuki H, Beppu S, Terada H, Sawabe M, Kadowaki S, Sone M, Hanai N. Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab. Cancer Sci 2021;112:339-46. [PMID: 33078505 DOI: 10.1111/cas.14706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
350 Chaput N, Marabelle A. Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer. Eur Respir J 2015;46:1541-3. [PMID: 26621880 DOI: 10.1183/13993003.01595-2015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
351 Simeone E, Ascierto PA. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag 2017;4:175-8. [PMID: 30190923 DOI: 10.2217/mmt-2017-0018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
352 Yoshimura K, Inoue Y, Tsuchiya K, Karayama M, Yamada H, Iwashita Y, Kawase A, Tanahashi M, Ogawa H, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Lung Cancer 2020;141:21-31. [PMID: 31931443 DOI: 10.1016/j.lungcan.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
353 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
354 Marabelle A, Gray J. Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy: Tumor- and Immune-Targeted Monoclonal Antibodies. Pediatr Blood Cancer 2015;62:1317-25. [DOI: 10.1002/pbc.25508] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
355 Yuzhakova DV, Volchkova LN, Pogorelyy MV, Serebrovskaya EO, Shagina IA, Bryushkova EA, Nakonechnaya TO, Izosimova AV, Zavyalova DS, Karabut MM, Izraelson M, Samoylenko IV, Zagainov VE, Chudakov DM, Zagaynova EV, Sharonov GV. Measuring Intratumoral Heterogeneity of Immune Repertoires. Front Oncol 2020;10:512. [PMID: 32457825 DOI: 10.3389/fonc.2020.00512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
356 Palacios Calvo J, Albanell J, Rojo F, Ciruelos E, Aranda-López I, Cortés J, García-Caballero T, Martín M, López-García MÁ, Colomer R. [Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology]. Rev Esp Patol 2018;51:97-109. [PMID: 29602380 DOI: 10.1016/j.patol.2017.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
357 Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunol Res 2019;7:1837-48. [PMID: 31462408 DOI: 10.1158/2326-6066.CIR-19-0229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
358 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
359 Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. Biomed Res Int 2019;2019:9056417. [PMID: 31179334 DOI: 10.1155/2019/9056417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
360 Schatten H. Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer. Adv Exp Med Biol 2018;1096:185-94. [PMID: 30324354 DOI: 10.1007/978-3-319-99286-0_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
361 Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resistance Updates 2017;30:39-47. [DOI: 10.1016/j.drup.2017.02.001] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
362 Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97-103. [PMID: 29097493 DOI: 10.1126/science.aan4236] [Cited by in Crossref: 1482] [Cited by in F6Publishing: 1357] [Article Influence: 296.4] [Reference Citation Analysis]
363 Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, Ye F, Hua H. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Front Immunol 2020;11:622509. [PMID: 33633741 DOI: 10.3389/fimmu.2020.622509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
364 He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Suda K, Ren S, Wu C, Hou L, Zhou C, Hirsch FR. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. J Thorac Oncol 2017;12:814-23. [PMID: 28132868 DOI: 10.1016/j.jtho.2017.01.019] [Cited by in Crossref: 74] [Cited by in F6Publishing: 87] [Article Influence: 14.8] [Reference Citation Analysis]
365 Weenink B, Draaisma K, Ooi HZ, Kros JM, Sillevis Smitt PAE, Debets R, French PJ. Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Sci Rep 2019;9:14643. [PMID: 31601888 DOI: 10.1038/s41598-019-51063-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
366 Zanker DJ, Owen KL, Baschuk N, Spurling AJ, Parker BS. Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer. Cancer Immunol Immunother 2021;70:2125-38. [PMID: 33449132 DOI: 10.1007/s00262-021-02857-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
367 Zhang Y, Fang Z, Li R, Huang X, Liu Q. Design of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy. Cancers (Basel) 2019;11:E1314. [PMID: 31500086 DOI: 10.3390/cancers11091314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
368 Kopalli SR, Kang T, Lee K, Koppula S. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature. PRA 2019;14:100-12. [DOI: 10.2174/1574892813666181029142812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
369 Jacquelot N, Zitvogel L, Eggermont AM. Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'. Nat Commun 2018;9:2922. [PMID: 30050125 DOI: 10.1038/s41467-018-05048-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
370 Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovée JV. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 2016;29:1028-37. [PMID: 27312065 DOI: 10.1038/modpathol.2016.108] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
371 Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46. [PMID: 26241053 DOI: 10.1172/JCI80004] [Cited by in Crossref: 157] [Cited by in F6Publishing: 83] [Article Influence: 22.4] [Reference Citation Analysis]
372 Jin YB, Luo W, Zhang GY, Lin KR, Cui JH, Chen XP, Pan YM, Mao XF, Tang J, Wang YJ. TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma. Cancer Immunol Immunother 2018;67:1719-30. [PMID: 30155576 DOI: 10.1007/s00262-018-2237-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
373 Ock CY, Kim S, Keam B, Kim S, Ahn YO, Chung EJ, Kim JH, Kim TM, Kwon SK, Jeon YK, Jung KC, Kim DW, Wu HG, Sung MW, Heo DS. Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget 2017;8:97920-7. [PMID: 29228662 DOI: 10.18632/oncotarget.18542] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
374 Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 2017;9:eaak9679. [DOI: 10.1126/scitranslmed.aak9679] [Reference Citation Analysis]
375 Zhang S, Zhong M, Wang C, Xu Y, Gao WQ, Zhang Y. CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer. Cell Death Dis 2018;9:766. [PMID: 29991744 DOI: 10.1038/s41419-018-0796-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
376 Dufva O, Pölönen P, Brück O, Keränen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, Vähä-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Leppä S, Nykter M, Lohi O, Heinäniemi M, Mustjoki S. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell 2020;38:380-399.e13. [PMID: 32649887 DOI: 10.1016/j.ccell.2020.06.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
377 van Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM. Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol 2017;102:1017-34. [PMID: 28729358 DOI: 10.1189/jlb.5MR0217-059RR] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
378 Wang Y, Shen N, Wang Y, Li M, Zhang W, Fan L, Liu L, Tang Z, Chen X. Cisplatin nanoparticles boost abscopal effect of radiation plus anti-PD1 therapy. Biomater Sci 2021;9:3019-27. [PMID: 33656040 DOI: 10.1039/d1bm00112d] [Reference Citation Analysis]
379 Uzhachenko RV, Bharti V, Ouyang Z, Blevins A, Mont S, Saleh N, Lawrence HA, Shen C, Chen SC, Ayers GD, DeNardo DG, Arteaga C, Richmond A, Vilgelm AE. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Rep 2021;35:108944. [PMID: 33826903 DOI: 10.1016/j.celrep.2021.108944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Chen IX, Newcomer K, Pauken KE, Juneja VR, Naxerova K, Wu MW, Pinter M, Sen DR, Singer M, Sharpe AH, Jain RK. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proc Natl Acad Sci U S A 2020;117:23684-94. [PMID: 32907939 DOI: 10.1073/pnas.2002806117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
381 Poschke I, Flossdorf M, Offringa R. Next-generation TCR sequencing - a tool to understand T-cell infiltration in human cancers. J Pathol 2016;240:384-6. [PMID: 27569598 DOI: 10.1002/path.4800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
382 Aversa I, Malanga D, Fiume G, Palmieri C. Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. Int J Mol Sci 2020;21:E2378. [PMID: 32235561 DOI: 10.3390/ijms21072378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
383 Jin K, Qiu S, Jin D, Zhou X, Zheng X, Li J, Liao X, Yang L, Wei Q. Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database. Aging (Albany NY) 2021;13:1859-71. [PMID: 33465047 DOI: 10.18632/aging.103787] [Reference Citation Analysis]
384 Kim SI, Cassella CR, Byrne KT. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Front Immunol 2020;11:629722. [PMID: 33597954 DOI: 10.3389/fimmu.2020.629722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
385 Bordon Y. Tumour immunology: Checkpoint parley. Nat Rev Immunol 2015;15:5. [PMID: 25475446 DOI: 10.1038/nri3792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
386 Perea F, Sánchez-Palencia A, Gómez-Morales M, Bernal M, Concha Á, García MM, González-Ramírez AR, Kerick M, Martin J, Garrido F, Ruiz-Cabello F, Aptsiauri N. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 2018;9:4120-33. [PMID: 29423109 DOI: 10.18632/oncotarget.23469] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
387 Gkountela S, Szczerba B, Donato C, Aceto N. Recent advances in the biology of human circulating tumour cells and metastasis. ESMO Open 2016;1:e000078. [PMID: 27843628 DOI: 10.1136/esmoopen-2016-000078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
388 De Bousser E, Callewaert N, Festjens N. T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy. Cancers (Basel) 2021;13:6067. [PMID: 34885176 DOI: 10.3390/cancers13236067] [Reference Citation Analysis]
389 Meireson A, Tavernier SJ, Van Gassen S, Sundahl N, Demeyer A, Spaas M, Kruse V, Ferdinande L, Van Dorpe J, Hennart B, Allorge D, Haerynck F, Decaestecker K, Rottey S, Saeys Y, Ost P, Brochez L. Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers (Basel) 2021;13:2630. [PMID: 34071888 DOI: 10.3390/cancers13112630] [Reference Citation Analysis]
390 Noman MZ, Parpal S, Van Moer K, Xiao M, Yu Y, Viklund J, De Milito A, Hasmim M, Andersson M, Amaravadi RK, Martinsson J, Berchem G, Janji B. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv 2020;6:eaax7881. [PMID: 32494661 DOI: 10.1126/sciadv.aax7881] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 21.5] [Reference Citation Analysis]
391 Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu C, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 2020;12:eaaz3577. [DOI: 10.1126/scitranslmed.aaz3577] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
392 Zhang Y, Wu L, Li Z, Zhang W, Luo F, Chu Y, Chen G. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. Biomacromolecules 2018;19:2098-108. [DOI: 10.1021/acs.biomac.8b00305] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
393 Glorieux C, Xia X, He YQ, Hu Y, Cremer K, Robert A, Liu J, Wang F, Ling J, Chiao PJ, Huang P. Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol 2021;38:101780. [PMID: 33171331 DOI: 10.1016/j.redox.2020.101780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
394 Song Y, Li Z, Xue W, Zhang M. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy 2019;11:515-29. [DOI: 10.2217/imt-2018-0173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
395 Su Q, Sun Z, Zhang C, Hou Y, Cao B. PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. Oncotarget 2017;8:59677-89. [PMID: 28938671 DOI: 10.18632/oncotarget.19641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
396 Kwak M, Erdag G, Slingluff CL Jr. Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Sci Rep 2020;10:18336. [PMID: 33110110 DOI: 10.1038/s41598-020-74996-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
397 Hsieh AH, Faithfull S, Brown MP. Risk of cumulative toxicity after complete melanoma response with pembrolizumab. BMJ Case Rep 2017;2017:bcr2016218308. [PMID: 28148549 DOI: 10.1136/bcr-2016-218308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
398 Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer 2018;119:950-60. [PMID: 30318514 DOI: 10.1038/s41416-018-0220-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 15.0] [Reference Citation Analysis]
399 Martínez Allo VC, Hauk V, Sarbia N, Pinto NA, Croci DO, Dalotto-Moreno T, Morales RM, Gatto SG, Manselle Cocco MN, Stupirski JC, Deladoey Á, Maronna E, Marcaida P, Durigan V, Secco A, Mamani M, Dos Santos A, Catalán Pellet A, Pérez Leiros C, Rabinovich GA, Toscano MA. Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits. Proc Natl Acad Sci U S A 2020;117:6630-9. [PMID: 32161138 DOI: 10.1073/pnas.1922778117] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
400 Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ. Genomic Instability in Multiple Myeloma. Trends Cancer 2020;6:858-73. [PMID: 32487486 DOI: 10.1016/j.trecan.2020.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
401 Ribas A, Algazi A, Ascierto PA, Butler MO, Chandra S, Gordon M, Hernandez-Aya L, Lawrence D, Lutzky J, Miller WH Jr, Campbell KM, Delafont B, Marshall S, Mueller N, Robert C. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat Commun 2020;11:6262. [PMID: 33288749 DOI: 10.1038/s41467-020-19810-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
402 D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol 2016;6:212. [PMID: 27774435 DOI: 10.3389/fonc.2016.00212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
403 Giraldo NA, Peske JD, Sautès-fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Arch 2019;474:463-74. [DOI: 10.1007/s00428-018-02517-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
404 Bahrambeigi S, Molaparast M, Sohrabi F, Seifi L, Faraji A, Fani S, Shafiei-Irannejad V. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. Immunol Lett 2020;220:32-7. [PMID: 31982460 DOI: 10.1016/j.imlet.2020.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
405 Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, Paño JR, Ramírez A, Sesma A, Torres-Ramón I, Yubero A, Pardo J, Martínez-Lostao L. Intratumoral Versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Cells 2020;9:E1525. [PMID: 32580514 DOI: 10.3390/cells9061525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
406 Kim CG, Hong MH, Kim KH, Seo IH, Ahn BC, Pyo KH, Synn CB, Yoon HI, Shim HS, Lee YI, Choi SJ, Lee YJ, Kim EJ, Kim Y, Kwak JE, Jung J, Park SH, Paik S, Shin EC, Kim HR. Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. Eur J Cancer 2021;143:113-26. [PMID: 33302114 DOI: 10.1016/j.ejca.2020.10.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
407 Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy. Cancers (Basel) 2020;12:E3729. [PMID: 33322522 DOI: 10.3390/cancers12123729] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
408 Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, Zucali PA. Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? Curr Oncol Rep 2021;23:147. [PMID: 34748099 DOI: 10.1007/s11912-021-01140-9] [Reference Citation Analysis]
409 Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. Front Oncol 2021;11:641428. [PMID: 34268109 DOI: 10.3389/fonc.2021.641428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
410 Cheng H, Onder L, Cupovic J, Boesch M, Novkovic M, Pikor N, Tarantino I, Rodriguez R, Schneider T, Jochum W, Brutsche M, Ludewig B. CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses. Journal of Allergy and Clinical Immunology 2018;142:1257-1271.e4. [DOI: 10.1016/j.jaci.2017.12.998] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
411 Snyder A, Pamer E, Wolchok J. IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy? Science. 2015;350:1031-1032. [PMID: 26612936 DOI: 10.1126/science.aad7706] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
412 Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. J Immunother Cancer 2019;7:32. [PMID: 30728077 DOI: 10.1186/s40425-019-0504-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
413 van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N. Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers (Basel) 2021;13:2249. [PMID: 34067105 DOI: 10.3390/cancers13092249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
414 Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B. Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. Oral Oncol 2016;61:166-76. [PMID: 27614589 DOI: 10.1016/j.oraloncology.2016.08.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
415 Chae YK, Oh MS, Giles FJ. Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist 2018;23:410-21. [PMID: 29242279 DOI: 10.1634/theoncologist.2017-0354] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
416 Shirasu H, Ono A, Omae K, Nakashima K, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Takahashi T. CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma. Tumour Biol 2018;40:101042831876042. [DOI: 10.1177/1010428318760420] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
417 Sullivan RJ, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi FS, Lewis KD, Tawbi HA, Hernandez G, Wongchenko MJ, Chang Y, Roberts L, Ballinger M, Yan Y, Cha E, Hwu P. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med 2019;25:929-35. [DOI: 10.1038/s41591-019-0474-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 32.7] [Reference Citation Analysis]
418 Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol 2017;198:3507-14. [PMID: 28341670 DOI: 10.4049/jimmunol.1502672] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
419 Borrull A, Allard B, Wijkhuisen A, Herbet A, Lamourette P, Birouk W, Leiber D, Tanfin Z, Ducancel F, Boquet D, Couraud JY, Robin P. Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. MAbs 2016;8:1371-85. [PMID: 27390909 DOI: 10.1080/19420862.2016.1208865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
420 Newman AM, Alizadeh AA. High-throughput genomic profiling of tumor-infiltrating leukocytes. Curr Opin Immunol 2016;41:77-84. [PMID: 27372732 DOI: 10.1016/j.coi.2016.06.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
421 Karime C, Wang J, Woodhead G, Mody K, Hennemeyer CT, Borad MJ, Mahadevan D, Chandana SR, Babiker H. Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34913781 DOI: 10.1080/13543784.2022.2019706] [Reference Citation Analysis]
422 Xu Y, Cai Y, Zu J, Wang X, Wang Y, Sun C, Guo Y, Shao G, Yang Z, Qiu S, Ma K. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report. Immunotherapy 2020;12:175-81. [PMID: 32064977 DOI: 10.2217/imt-2019-0090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, Schroeder C, Demidov G, Riedel T, Fehrenbacher B, Schaller M, Forschner A, Eigentler T, Niessner H, Sinnberg T, Böhm KS, Hömberg N, Braumüller H, Dauch D, Zwirner S, Zender L, Sonanini D, Geishauser A, Bauer J, Eichner M, Jarick KJ, Beilhack A, Biskup S, Döcker D, Schadendorf D, Quintanilla-Martinez L, Pichler BJ, Kneilling M, Mocikat R, Röcken M. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 2020;11:1335. [PMID: 32165639 DOI: 10.1038/s41467-020-14987-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
424 Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel) 2019;11:E935. [PMID: 31277279 DOI: 10.3390/cancers11070935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
425 Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 2020;20:1185. [PMID: 33272262 DOI: 10.1186/s12885-020-07690-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
426 Xu J, Sun HH, Fletcher CD, Hornick JL, Morgan EA, Freeman GJ, Hodi FS, Pinkus GS, Rodig SJ. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology 2016;40:443-53. [DOI: 10.1097/pas.0000000000000590] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
427 Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: 'Beyond the T cell'. J Immunother Cancer 2021;9:e001460. [PMID: 33468555 DOI: 10.1136/jitc-2020-001460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
428 Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC, Ring KL. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol 2018;31:1282-90. [PMID: 29559741 DOI: 10.1038/s41379-018-0039-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
429 Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S. Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. J Med Chem 2019;62:1715-30. [PMID: 30247903 DOI: 10.1021/acs.jmedchem.8b00990] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
430 Zhang J, Hu X, Wang J, Sahu AD, Cohen D, Song L, Ouyang Z, Fan J, Wang B, Fu J, Gu S, Sade-Feldman M, Hacohen N, Li W, Ying X, Li B, Liu XS. Immune receptor repertoires in pediatric and adult acute myeloid leukemia. Genome Med 2019;11:73. [PMID: 31771646 DOI: 10.1186/s13073-019-0681-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
431 Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Sci Rep 2019;9:6136. [PMID: 30992475 DOI: 10.1038/s41598-019-42237-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 15.7] [Reference Citation Analysis]
432 Sweis RF, Luke JJ. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res 2017;120:1-9. [PMID: 28323141 DOI: 10.1016/j.phrs.2017.03.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
433 Gulla SK, Kotcherlakota R, Nimushakavi S, Nimmu NV, Khalid S, Patra CR, Chaudhuri A. Au-CGKRK Nanoconjugates for Combating Cancer through T-Cell-Driven Therapeutic RNA Interference. ACS Omega 2018;3:8663-76. [PMID: 31458997 DOI: 10.1021/acsomega.8b01051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
434 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
435 Berinstein NL, McNamara M, Nguyen A, Egan J, Wolf GT. Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology 2018;7:e1423173. [PMID: 29721379 DOI: 10.1080/2162402X.2017.1423173] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
436 Yuba E, Fukaya Y, Yanagihara S, Kasho N, Harada A. Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. Pharmaceutics 2020;12:E754. [PMID: 32796567 DOI: 10.3390/pharmaceutics12080754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
437 Xia D, Casanova R, Machiraju D, McKee TD, Weder W, Beck AH, Soltermann A. Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. Sci Rep 2018;8:3941. [PMID: 29500362 DOI: 10.1038/s41598-018-22254-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
438 Zhou YW, Zhu YJ, Wang MN, Xie Y, Chen CY, Zhang T, Xia F, Ding ZY, Liu JY. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol 2019;10:1350. [PMID: 31849640 DOI: 10.3389/fphar.2019.01350] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
439 Hellmann MD, Friedman CF, Wolchok JD. Combinatorial Cancer Immunotherapies. Adv Immunol 2016;130:251-77. [PMID: 26923003 DOI: 10.1016/bs.ai.2015.12.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
440 Andreatta M, Corria-Osorio J, Müller S, Cubas R, Coukos G, Carmona SJ. Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nat Commun 2021;12:2965. [PMID: 34017005 DOI: 10.1038/s41467-021-23324-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
441 Kimura H, Tounai Y, Nagato K, Morimoto JI, Tounai Y. A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient. J Thorac Oncol 2017;12:e128-30. [PMID: 28748825 DOI: 10.1016/j.jtho.2017.04.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
442 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
443 Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res 2019;25:4592-602. [PMID: 30824587 DOI: 10.1158/1078-0432.CCR-18-1538] [Cited by in Crossref: 141] [Cited by in F6Publishing: 99] [Article Influence: 47.0] [Reference Citation Analysis]
444 Crispin JC, Tsokos GC. Cancer immunosurveillance by CD8 T cells. F1000Res. 2020;9. [PMID: 32089832 DOI: 10.12688/f1000research.21150.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
445 Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther 2020;20:981-9. [PMID: 32450725 DOI: 10.1080/14712598.2020.1769063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
446 Xu B, Jungbluth AA, Frosina D, Alzumaili B, Aleynick N, Slodkowska E, Higgins K, Ho A, Morris L, Ghossein R, Katabi N. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. Histopathology 2019;75:672-82. [PMID: 31237963 DOI: 10.1111/his.13944] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
447 Ye X, Waite JC, Dhanik A, Gupta N, Zhong M, Adler C, Malahias E, Ni M, Wei Y, Gurer C, Zhang W, Macdonald LE, Murphy AJ, Sleeman MA, Skokos D. Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model. Oncoimmunology 2020;9:1758602. [PMID: 32923116 DOI: 10.1080/2162402X.2020.1758602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
448 Rosinsky C, Antony PA. A role for pre-mNK cells in tumor progression. J Immunother Cancer 2016;4:16. [PMID: 26981246 DOI: 10.1186/s40425-016-0120-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
449 Elias R, Kapur P, Pedrosa I, Brugarolas J. Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back. Clin Genitourin Cancer 2018;16:485-8. [PMID: 30100272 DOI: 10.1016/j.clgc.2018.07.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
450 Sitnikova SI, Munnings-Tomes S, Galvani E, Kentner S, Mulgrew K, Rands C, España Agustí J, Zhang T, Ilieva KM, Rosignoli G, Ghadially H, Robinson MJ, Slidel T, Wilkinson RW, Dovedi SJ. Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models. J Immunother Cancer 2021;9:e002894. [PMID: 34145033 DOI: 10.1136/jitc-2021-002894] [Reference Citation Analysis]
451 Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J Immunother Cancer 2019;7:225. [PMID: 31439037 DOI: 10.1186/s40425-019-0665-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
452 Nakayama K, Onishi H, Fujimura A, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Koga S, Fujimoto Y, Nakashima K, Nakamura M. NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes. Cell Immunol 2020;358:104237. [PMID: 33137650 DOI: 10.1016/j.cellimm.2020.104237] [Reference Citation Analysis]
453 Sato F, Ono T, Kawahara A, Kawaguchi T, Tanaka H, Shimamatsu K, Kakuma T, Akiba J, Umeno H, Yano H. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol 2019;72:542-9. [PMID: 31113825 DOI: 10.1136/jclinpath-2019-205818] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
454 Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
455 Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y. IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 2018;6:1014-24. [PMID: 29980536 DOI: 10.1158/2326-6066.CIR-17-0710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
456 Zhang C, Zhang G, Sun N, Zhang Z, Xue L, Zhang Z, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Wang L, Che Y, Wang F, Wang S, Gao S, Xue Q, Zhang Y, He J. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduct Target Ther 2020;5:182. [PMID: 32883946 DOI: 10.1038/s41392-020-00221-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
457 Ju A, Lee SW, Lee YE, Han KC, Kim JC, Shin SC, Park HJ, EunKyeong Kim E, Hong S, Jang M. A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials 2019;217:119298. [PMID: 31280073 DOI: 10.1016/j.biomaterials.2019.119298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
458 Bissonnette RP, Cesario RM, Goodenow B, Shojaei F, Gillings M. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors. BMC Cancer 2021;21:969. [PMID: 34461854 DOI: 10.1186/s12885-021-08702-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Osawa Y, Kojika E, Nishikawa K, Kimura M, Osakaya S, Miyauchi H, Kanto T, Kawakami Y, Kimura K. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget 2019;10:3013-26. [PMID: 31105882 DOI: 10.18632/oncotarget.26892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
460 Kim HD, Jeong S, Park S, Lee YJ, Ju YS, Kim D, Song GW, Lee JH, Kim SY, Shin J, Shin EC, Hwang S, Yoo C, Park SH. Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma. Liver Int 2021;41:764-76. [PMID: 33548061 DOI: 10.1111/liv.14814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
461 Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol. 2015;6:310. [PMID: 26167163 DOI: 10.3389/fimmu.2015.00310] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 17.4] [Reference Citation Analysis]
462 Phillips D, Matusiak M, Gutierrez BR, Bhate SS, Barlow GL, Jiang S, Demeter J, Smythe KS, Pierce RH, Fling SP, Ramchurren N, Cheever MA, Goltsev Y, West RB, Khodadoust MS, Kim YH, Schürch CM, Nolan GP. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun 2021;12:6726. [PMID: 34795254 DOI: 10.1038/s41467-021-26974-6] [Reference Citation Analysis]
463 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
464 Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, Gronchi A, Astolfi A, Pantaleo MA, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. Journal of Investigative Dermatology 2017;137:484-93. [DOI: 10.1016/j.jid.2016.06.634] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
465 Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 2016;44:1255-69. [PMID: 27332730 DOI: 10.1016/j.immuni.2016.06.001] [Cited by in Crossref: 438] [Cited by in F6Publishing: 442] [Article Influence: 87.6] [Reference Citation Analysis]
466 Kitano S, Nakayama T, Yamashita M. Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2018;8:270. [PMID: 30073150 DOI: 10.3389/fonc.2018.00270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
467 Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017;8:15095. [PMID: 28447602 DOI: 10.1038/ncomms15095] [Cited by in Crossref: 211] [Cited by in F6Publishing: 206] [Article Influence: 42.2] [Reference Citation Analysis]
468 Bellone M, Elia AR. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. Cytokine Growth Factor Rev 2017;36:17-24. [PMID: 28606732 DOI: 10.1016/j.cytogfr.2017.06.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
469 Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, Klautke G, Laban S, Brunner T, Hinke A, Becker I, Frey B, Semrau S, Geppert CI, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Fietkau R. Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8. J Immunother Cancer 2020;8:e001378. [PMID: 33023982 DOI: 10.1136/jitc-2020-001378] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
470 Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015;12:74-8. [PMID: 26175922 DOI: 10.7497/j.issn.2095-3941.2015.0022] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
471 Wieder T, Eigentler T, Brenner E, Röcken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol 2018;142:1403-14. [PMID: 29596939 DOI: 10.1016/j.jaci.2018.02.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
472 Gerber HP, Sibener LV, Lee LJ, Gee MH. Identification of Antigenic Targets. Trends Cancer 2020;6:299-318. [PMID: 32209445 DOI: 10.1016/j.trecan.2020.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
473 Zhu C, Dai Y, Zhang H, Ruan Y, Zhou Y, Dai Y, Fan L, Jia T, Lu H, Chen Q. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis. Diagn Pathol 2021;16:84. [PMID: 34465342 DOI: 10.1186/s13000-021-01139-7] [Reference Citation Analysis]
474 [DOI: 10.1101/824482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
475 Neubert NJ, Tillé L, Martignier C, Fuertes Marraco SA, Speiser DE. Analysis of cancer cell-intrinsic immune regulation in response to CD8+ T cell attack. Methods Enzymol 2020;631:443-66. [PMID: 31948563 DOI: 10.1016/bs.mie.2019.05.035] [Reference Citation Analysis]
476 Chen Y, Zhang C, Peng Z, Qi C, Gong J, Zhang X, Li J, Shen L. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Front Oncol 2021;11:589022. [PMID: 34141607 DOI: 10.3389/fonc.2021.589022] [Reference Citation Analysis]
477 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
478 Kaesler S, Wölbing F, Kempf WE, Skabytska Y, Köberle M, Volz T, Sinnberg T, Amaral T, Möckel S, Yazdi A, Metzler G, Schaller M, Hartmann K, Weide B, Garbe C, Rammensee HG, Röcken M, Biedermann T. Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight 2019;4:125057. [PMID: 31578309 DOI: 10.1172/jci.insight.125057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
479 Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos AI, Kleiner R, Moura LIF, Zupančič E, Viana AS, Doron H, Gois PMP, Erez N, Jung S, Satchi-Fainaro R, Florindo HF. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol 2019;14:891-901. [PMID: 31384037 DOI: 10.1038/s41565-019-0512-0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 26.7] [Reference Citation Analysis]
480 Polyakova A, Kuznetsova K, Moshkovskii S. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. Expert Review of Proteomics 2015;12:533-41. [DOI: 10.1586/14789450.2015.1070100] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
481 Li N, Wang J, Zhang N, Zhuang M, Zong Z, Zou J, Li G, Wang X, Zhou H, Zhang L, Shi Y. Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother 2018;67:271-83. [PMID: 29090321 DOI: 10.1007/s00262-017-2086-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
482 Singh MP, Sethuraman SN, Miller C, Malayer J, Ranjan A. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors. Theranostics 2021;11:540-54. [PMID: 33391491 DOI: 10.7150/thno.49517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
483 Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med 2018;16:86. [PMID: 29615076 DOI: 10.1186/s12967-018-1460-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
484 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
485 Murray AA, Wang C, Fiering S, Steinmetz NF. In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. Mol Pharm 2018;15:3700-16. [PMID: 29798673 DOI: 10.1021/acs.molpharmaceut.8b00316] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
486 Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book 2016;35:e493-503. [PMID: 27249758 DOI: 10.1200/EDBK_160766] [Cited by in Crossref: 21] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
487 Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature 2017;541:321-30. [DOI: 10.1038/nature21349] [Reference Citation Analysis]
488 Guo XY, Zhang GH, Wang ZN, Duan H, Xie T, Liang L, Cui R, Hu HR, Wu Y, Dong JJ, He ZQ, Mou YG. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling. Aging (Albany NY) 2021;13:3501-17. [PMID: 33429364 DOI: 10.18632/aging.202282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
489 Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res 2015;21:3052-60. [PMID: 25788491 DOI: 10.1158/1078-0432.CCR-14-3073] [Cited by in Crossref: 134] [Cited by in F6Publishing: 85] [Article Influence: 19.1] [Reference Citation Analysis]
490 Victoor J, Borght SV, Spans L, Lehnert S, Brems H, Laenen A, Vergote I, Van Gorp T, Van Nieuwenhuysen E, Han S, Timmerman S, Van Rompuy AS, Vanden Bempt I. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. Gynecol Oncol 2021;162:694-701. [PMID: 34253388 DOI: 10.1016/j.ygyno.2021.06.030] [Reference Citation Analysis]
491 Garris CS, Luke JJ. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response. Clin Cancer Res 2020;26:3901-7. [PMID: 32332013 DOI: 10.1158/1078-0432.CCR-19-1321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
492 Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A, Matias-Guiu X. Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 2017;145:200-7. [PMID: 28040204 DOI: 10.1016/j.ygyno.2016.12.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
493 Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Takagi H, Hagiwara D, Goto M, Suga H, Banno R, Takahashi M, Nishikawa H, Arima H. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med 2021;13:eabb7495. [PMID: 33980577 DOI: 10.1126/scitranslmed.abb7495] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
494 Ma VT, Daignault-Newton S, Waninger JJ, Journey S, Chopra Z, Tezel A, Redman BG, Fecher LA, Green MD, Alva AS, Lao CD. The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. Pigment Cell Melanoma Res 2021;34:629-40. [PMID: 33128316 DOI: 10.1111/pcmr.12944] [Reference Citation Analysis]
495 Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28:874-881. [PMID: 28168303 DOI: 10.1093/annonc/mdx008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 129] [Article Influence: 26.0] [Reference Citation Analysis]
496 Dwary AD, Master S, Patel A, Cole C, Mansour R, Mills G, Koshy N, Peddi P, Burton G, Hammoud D, Beedupalli K. Excellent response to chemotherapy post immunotherapy. Oncotarget 2017;8:91795-802. [PMID: 29207685 DOI: 10.18632/oncotarget.20030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
497 Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett 2020;477:19-30. [PMID: 32120023 DOI: 10.1016/j.canlet.2020.02.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
498 Alambeladi S, Hosseiny S, Jafarinia M, Dianatpour M. Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells. Iran J Basic Med Sci 2021;24:44-50. [PMID: 33643569 DOI: 10.22038/ijbms.2020.48566.11146] [Reference Citation Analysis]
499 Goding SR, Wilson KA, Rosinsky C, Antony PA. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. J Immunol 2018;200:3304-11. [PMID: 29602773 DOI: 10.4049/jimmunol.1701617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
500 Valpione S, Mundra PA, Galvani E, Campana LG, Lorigan P, De Rosa F, Gupta A, Weightman J, Mills S, Dhomen N, Marais R. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun 2021;12:4098. [PMID: 34215730 DOI: 10.1038/s41467-021-24343-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
501 Lim YH, Moscato Z, Choate KA. Mosaicism in Cutaneous Disorders. Annu Rev Genet 2017;51:123-41. [PMID: 29178821 DOI: 10.1146/annurev-genet-121415-121955] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
502 Yang-Chun F, Zhen-Zhen C, Yan-Chun H, Xiu-Min M. Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients. Medicine (Baltimore) 2017;96:e7270. [PMID: 28640134 DOI: 10.1097/MD.0000000000007270] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
503 Blessin NC, Li W, Mandelkow T, Jansen HL, Yang C, Raedler JB, Simon R, Büscheck F, Dum D, Luebke AM, Hinsch A, Möller K, Menz A, Bernreuther C, Lebok P, Clauditz T, Sauter G, Marx A, Uhlig R, Wilczak W, Minner S, Krech T, Fraune C, Höflmayer D, Burandt E, Steurer S. Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers. Cell Oncol (Dordr) 2021;44:793-803. [PMID: 33864611 DOI: 10.1007/s13402-021-00601-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
504 Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA, Morris LG. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829. [PMID: 27777979 DOI: 10.1172/jci.insight.89829] [Cited by in Crossref: 283] [Cited by in F6Publishing: 263] [Article Influence: 47.2] [Reference Citation Analysis]
505 Kim KH, Kim CG, Shin EC. Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. Immune Netw 2020;20:e8. [PMID: 32158596 DOI: 10.4110/in.2020.20.e8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
506 Naidoo J, Li BT, Schindler K, Page DB. What does the future hold for immunotherapy in cancer? Ann Transl Med 2016;4:177. [PMID: 27275490 DOI: 10.21037/atm.2016.04.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
507 Audrey-Bayan C, Trager MH, Gartrell-Corrado RD, Rizk EM, Pradhan J, Silverman AM, Lopez A, Marks DK, Niedt G, Geskin LJ, Saenger YM. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec. Melanoma Res 2020;30:410-5. [PMID: 32379409 DOI: 10.1097/CMR.0000000000000661] [Reference Citation Analysis]
508 Cho S, Kim SB, Lee Y, Song EC, Kim U, Kim HY, Suh JH, Goughnour PC, Kim Y, Yoon I, Shin NY, Kim D, Kim IK, Kang CY, Jang SY, Kim MH, Kim S. Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1. J Immunother Cancer 2020;8:e000277. [PMID: 32461342 DOI: 10.1136/jitc-2019-000277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
509 Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35-44. [PMID: 26997480 DOI: 10.1016/j.cell.2016.02.065] [Cited by in Crossref: 1279] [Cited by in F6Publishing: 1174] [Article Influence: 213.2] [Reference Citation Analysis]
510 Naghavi AO, Johnstone PA, Kim S. Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. Curr Probl Cancer 2016;40:38-67. [PMID: 26656977 DOI: 10.1016/j.currproblcancer.2015.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
511 Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655-668. [PMID: 28653677 DOI: 10.1038/nrclinonc.2017.88] [Cited by in Crossref: 373] [Cited by in F6Publishing: 350] [Article Influence: 74.6] [Reference Citation Analysis]
512 Martínez-Pérez E, Molina-Vila MA, Marino-Buslje C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. NPJ Precis Oncol 2021;5:31. [PMID: 33850256 DOI: 10.1038/s41698-021-00169-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clin Cancer Res 2017;23:370-8. [PMID: 27440266 DOI: 10.1158/1078-0432.CCR-16-0150] [Cited by in Crossref: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
514 Spranger S, Sivan A, Corrales L, Gajewski TF. Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.Adv Immunol. 2016;130:75-93. [PMID: 26923000 DOI: 10.1016/bs.ai.2015.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 8.7] [Reference Citation Analysis]
515 Byers J, Yin H, Rytting H, Logan S, He M, Yu Z, Wang D, Warren M, Mangray S, Dehner LP, Zhou S. PD-L1 expression in angiomatoid fibrous histiocytoma. Sci Rep 2021;11:2183. [PMID: 33500467 DOI: 10.1038/s41598-021-81746-y] [Reference Citation Analysis]
516 Rollins MR, Spartz EJ, Stromnes IM. T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Curr Protoc Immunol 2020;129:e97. [PMID: 32432843 DOI: 10.1002/cpim.97] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
517 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
518 Hope JL, Stairiker CJ, Bae EA, Otero DC, Bradley LM. Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation. Front Immunol 2019;10:1595. [PMID: 31379821 DOI: 10.3389/fimmu.2019.01595] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
519 Hoekstra ME, Bornes L, Dijkgraaf FE, Philips D, Pardieck IN, Toebes M, Thommen DS, van Rheenen J, Schumacher TNM. Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFNγ. Nat Cancer 2020;1:291-301. [PMID: 32566933 DOI: 10.1038/s43018-020-0036-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
520 Iwase T, Blenman KRM, Li X, Reisenbichler E, Seitz R, Hout D, Nielsen TJ, Schweitzer BL, Bailey DB, Shen Y, Zhang X, Pusztai L, Ueno NT. A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:4839. [PMID: 34638323 DOI: 10.3390/cancers13194839] [Reference Citation Analysis]
521 Peri A, Greenstein E, Alon M, Pai JA, Dingjan T, Reich-Zeliger S, Barnea E, Barbolin C, Levy R, Arnedo-Pac C, Kalaora S, Dassa B, Feldmesser E, Shang P, Greenberg P, Levin Y, Benedek G, Levesque MP, Adams DJ, Lotem M, Wilmott JS, Scolyer RA, Jönsson GB, Admon A, Rosenberg SA, Cohen CJ, Niv MY, Lopez-Bigas N, Satpathy AT, Friedman N, Samuels Y. Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. J Clin Invest 2021;131:e129466. [PMID: 34651586 DOI: 10.1172/JCI129466] [Reference Citation Analysis]
522 Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, Gong G. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget 2016;7:30119-32. [PMID: 27121061 DOI: 10.18632/oncotarget.8798] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
523 Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018;6:78. [PMID: 30081947 DOI: 10.1186/s40425-018-0381-3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
524 Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, Holmström MO, Hendel HW, Ehrnrooth E, Zocca MB, Pedersen AW, Andersen MH, Svane IM. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med 2021;27:2212-23. [PMID: 34887574 DOI: 10.1038/s41591-021-01544-x] [Reference Citation Analysis]
525 Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangère V, Truntzer C, Ghiringhelli F. Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. Oncoimmunology 2021;10:1957603. [PMID: 34377595 DOI: 10.1080/2162402X.2021.1957603] [Reference Citation Analysis]
526 Acharya AP, Sinha M, Ratay ML, Ding X, Balmert SC, Workman CJ, Wang Y, Vignali DAA, Little SR. Localized Multi-Component Delivery Platform Generates Local and Systemic Anti-Tumor Immunity. Adv Funct Mater 2017;27:1604366. [DOI: 10.1002/adfm.201604366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
527 Cheng W, Fu D, Xu F, Zhang Z. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis 2018;7:2. [PMID: 29358573 DOI: 10.1038/s41389-017-0013-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
528 Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol 2019;10:2109. [PMID: 31552045 DOI: 10.3389/fimmu.2019.02109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
529 Nagy NA, de Haas AM, Geijtenbeek TBH, van Ree R, Tas SW, van Kooyk Y, de Jong EC. Therapeutic Liposomal Vaccines for Dendritic Cell Activation or Tolerance. Front Immunol 2021;12:674048. [PMID: 34054859 DOI: 10.3389/fimmu.2021.674048] [Reference Citation Analysis]
530 Lee JJ, Chu E. Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018;17:258-273. [PMID: 30072278 DOI: 10.1016/j.clcc.2018.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
531 Rao SV, Moran AE, Graff JN. Predictors of response and resistance to checkpoint inhibitors in solid tumors. Ann Transl Med 2017;5:468. [PMID: 29285501 DOI: 10.21037/atm.2017.09.35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
532 Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54:367-386.e8. [PMID: 33567262 DOI: 10.1016/j.immuni.2021.01.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
533 Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:599-608. [PMID: 30688989 DOI: 10.1007/s00262-019-02299-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
534 Mahler C, Andrews M, Henson SM, Gnanapavan S. Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 2020;7:e756. [PMID: 32434801 DOI: 10.1212/NXI.0000000000000756] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
535 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e1008814. [PMID: 26137403 DOI: 10.1080/2162402X.2015.1008814] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
536 Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, Garber J, Joffe S, Lindeman N, Wagle N, Garraway LA, Van Allen EM. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med 2016;8:79. [PMID: 27460824 DOI: 10.1186/s13073-016-0333-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 16.2] [Reference Citation Analysis]
537 Wang C, Xue W, Zhang H, Fu Y. Identification of candidate genes encoding tumor-specific neoantigens in early- and late-stage colon adenocarcinoma. Aging (Albany NY) 2021;13:4024-44. [PMID: 33428592 DOI: 10.18632/aging.202370] [Reference Citation Analysis]
538 Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, Jöhrer K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 2016;9:116. [PMID: 27809856 DOI: 10.1186/s13045-016-0345-3] [Cited by in Crossref: 100] [Cited by in F6Publishing: 99] [Article Influence: 16.7] [Reference Citation Analysis]
539 Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev 2018;65:54-64. [PMID: 29547766 DOI: 10.1016/j.ctrv.2018.02.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
540 Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, McHugh JB; INSPIRE Trial Clinical Investigators. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral Oncol 2020;111:104928. [PMID: 32738599 DOI: 10.1016/j.oraloncology.2020.104928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
541 Joshi K, Chain BM, Peggs KS, Quezada SA. The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. Cold Spring Harb Perspect Med 2018;8:a027086. [PMID: 28630228 DOI: 10.1101/cshperspect.a027086] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
542 Knapp DW, Dhawan D, Ramos-Vara JA, Ratliff TL, Cresswell GM, Utturkar S, Sommer BC, Fulkerson CM, Hahn NM. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans. Front Oncol 2019;9:1493. [PMID: 32039002 DOI: 10.3389/fonc.2019.01493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
543 Feng C, Cao LJ, Song HF, Xu P, Chen H, Xu JC, Zhu XY, Zhang XG, Wang XF. Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. Viral Immunol 2015;28:418-24. [PMID: 26266813 DOI: 10.1089/vim.2015.0062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
544 Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J. Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. J Immunother Cancer 2016;4:10. [PMID: 26885372 DOI: 10.1186/s40425-016-0111-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
545 Bou-Dargham MJ, Draughon S, Cantrell V, Khamis ZI, Sang QA. Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy. J Cancer 2021;12:6949-63. [PMID: 34729098 DOI: 10.7150/jca.64205] [Reference Citation Analysis]
546 Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. J Natl Cancer Inst 2018;110:787-90. [PMID: 29365144 DOI: 10.1093/jnci/djx277] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
547 Liu Y, He Y. A narrative review of chimeric antigen receptor-T (CAR-T) cell therapy for lung cancer. Ann Transl Med 2021;9:808. [PMID: 34268421 DOI: 10.21037/atm-20-5419] [Reference Citation Analysis]
548 Blank C. Biomarkers for outcome upon MAPK inhibition in melanoma. Lancet Oncol 2016;17:1634-6. [PMID: 27924744 DOI: 10.1016/S1470-2045(16)30593-9] [Reference Citation Analysis]
549 Tu MM, Ng TL, De Jong FC, Zuiverloon TCM, Fazzari FGT, Theodorescu D. Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. Bladder Cancer 2019;5:131-45. [PMID: 33365377 DOI: 10.3233/BLC-190218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
550 Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. The Breast 2017;35:142-50. [DOI: 10.1016/j.breast.2017.07.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 10.4] [Reference Citation Analysis]
551 Ou YC, Wen X, Johnson CA, Shae D, Ayala OD, Webb JA, Lin EC, DeLapp RC, Boyd KL, Richmond A, Mahadevan-Jansen A, Rafat M, Wilson JT, Balko JM, Tantawy MN, Vilgelm AE, Bardhan R. Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies. ACS Nano 2020;14:651-63. [PMID: 31851488 DOI: 10.1021/acsnano.9b07326] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
552 Kwak M, Erdag G, Leick KM, Bekiranov S, Engelhard VH, Slingluff CL. Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. J Transl Med 2021;19:371. [PMID: 34454518 DOI: 10.1186/s12967-021-03044-5] [Reference Citation Analysis]
553 Zhang H, Houghton AM. Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. Pharmacol Ther 2021;217:107662. [PMID: 32805297 DOI: 10.1016/j.pharmthera.2020.107662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
554 Mao L, Tang Y, Deng MJ, Huang CT, Lan D, Nong WZ, Li L, Wang Q. A combined biomarker panel shows improved sensitivity and specificity for detection of ovarian cancer. J Clin Lab Anal 2022;:e24232. [PMID: 34995016 DOI: 10.1002/jcla.24232] [Reference Citation Analysis]
555 Tang B, Yang S. Involvement of Heparanase in Gastric Cancer Progression and Immunotherapy. Adv Exp Med Biol 2020;1221:351-63. [PMID: 32274717 DOI: 10.1007/978-3-030-34521-1_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
556 Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer 2019;132:107-13. [PMID: 31097082 DOI: 10.1016/j.lungcan.2019.03.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
557 Ahrends T, Spanjaard A, Pilzecker B, Bąbała N, Bovens A, Xiao Y, Jacobs H, Borst J. CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness. Immunity 2017;47:848-861.e5. [PMID: 29126798 DOI: 10.1016/j.immuni.2017.10.009] [Cited by in Crossref: 129] [Cited by in F6Publishing: 121] [Article Influence: 25.8] [Reference Citation Analysis]
558 Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016; Epub ahead of print. [PMID: 27137346 DOI: 10.1016/j.cllc.2016.03.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
559 Kuhlmann JD, Bachmann HS, Link T, Wimberger P, Kröber E, Thomssen C, Mallé B, Bethmann D, Vetter M, Kantelhardt EJ. Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. Sci Rep 2019;9:12594. [PMID: 31467295 DOI: 10.1038/s41598-019-47601-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
560 Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017;7:e1378842. [PMID: 29296541 DOI: 10.1080/2162402X.2017.1378842] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
561 Zhou Y, Zong H, Han L, Xie Y, Jiang H, Gilly J, Zhang B, Lu H, Chen J, Sun R, Pan Z, Zhu J. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J Exp Clin Cancer Res 2020;39:87. [PMID: 32398042 DOI: 10.1186/s13046-020-01564-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
562 Kiyohara E, Tanemura A, Nishioka M, Yamada M, Tanaka A, Yokomi A, Saito A, Sakura K, Nakajima T, Myoui A, Sakurai T, Kawakami Y, Kaneda Y, Katayama I. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. Cancer Immunol Immunother 2020;69:1131-40. [PMID: 32047956 DOI: 10.1007/s00262-020-02509-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
563 Wischhusen J, Melero I, Fridman WH. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint.Front Immunol. 2020;11:951. [PMID: 32508832 DOI: 10.3389/fimmu.2020.00951] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
564 Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med 2016;375:819-29. [PMID: 27433843 DOI: 10.1056/NEJMoa1604958] [Cited by in Crossref: 1500] [Cited by in F6Publishing: 899] [Article Influence: 250.0] [Reference Citation Analysis]
565 Kakavand H, Wilmott JS, Long GV, Scolyer RA. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology 2016;48:194-202. [PMID: 27020392 DOI: 10.1016/j.pathol.2015.12.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
566 Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer 2021;9:e001698. [PMID: 33472857 DOI: 10.1136/jitc-2020-001698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
567 Schumacher TN, Kesmir C, van Buuren MM. Biomarkers in cancer immunotherapy. Cancer Cell 2015;27:12-4. [PMID: 25584891 DOI: 10.1016/j.ccell.2014.12.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 11.7] [Reference Citation Analysis]
568 Li J, Luo Y, Pu K. Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy. Angew Chem Int Ed 2021;60:12682-705. [DOI: 10.1002/anie.202008386] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
569 Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 2016;41:23-31. [PMID: 27240055 DOI: 10.1016/j.coi.2016.05.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 11.2] [Reference Citation Analysis]
570 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9] [Cited by in Crossref: 261] [Cited by in F6Publishing: 266] [Article Influence: 52.2] [Reference Citation Analysis]
571 Beg AA, Gray JE. HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types? Epigenomics 2016;8:1015-7. [PMID: 27410519 DOI: 10.2217/epi-2016-0066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
572 Kawakubo M, Cunningham TJ, Demehri S, Manstein D. Fractional Laser Releases Tumor-Associated Antigens in Poorly Immunogenic Tumor and Induces Systemic Immunity. Sci Rep 2017;7:12751. [PMID: 28986576 DOI: 10.1038/s41598-017-13095-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
573 Tang D, Park S, Zhao H. NITUMID: Nonnegative matrix factorization-based Immune-TUmor MIcroenvironment Deconvolution. Bioinformatics 2020;36:1344-50. [PMID: 31593244 DOI: 10.1093/bioinformatics/btz748] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
574 Meireson A, Devos M, Brochez L. IDO Expression in Cancer: Different Compartment, Different Functionality? Front Immunol 2020;11:531491. [PMID: 33072086 DOI: 10.3389/fimmu.2020.531491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
575 Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, O'Brien SA, Chun M, Noubade R, Eng J, Ma H, Muenz M, Li P, Alba BM, Thomas M, Cook K, Wang X, DeVoss J, Egen JG, Nolan-Stevaux O. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med 2021;13:eabd1524. [PMID: 34433637 DOI: 10.1126/scitranslmed.abd1524] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
576 Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. J Thorac Oncol 2021:S1556-0864(21)02373-X. [PMID: 34419685 DOI: 10.1016/j.jtho.2021.07.027] [Reference Citation Analysis]
577 Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology. 2017;7:e1364828. [PMID: 29296515 DOI: 10.1080/2162402x.2017.1364828] [Cited by in Crossref: 102] [Cited by in F6Publishing: 78] [Article Influence: 20.4] [Reference Citation Analysis]
578 Park SM, Youn JI. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res 2019;42:560-6. [PMID: 31147902 DOI: 10.1007/s12272-019-01165-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
579 Lavareze L, Scarini JF, de Lima-souza RA, Emerick C, de Sá RS, Aquino IG, Fernandes PM, Gonçalves MT, Helms MN, Altemani A, Egal ESA, Mariano FV. Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103605] [Reference Citation Analysis]
580 Sanchez K, Page D, McArthur HL. Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. Curr Probl Cancer 2016;40:151-62. [PMID: 27855963 DOI: 10.1016/j.currproblcancer.2016.09.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
581 Koustas E, Sarantis P, Papavassiliou AG, Karamouzis MV. The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. Biomolecules 2020;10:E666. [PMID: 32344837 DOI: 10.3390/biom10050666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
582 Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 2020;20:25-39. [PMID: 31570880 DOI: 10.1038/s41577-019-0218-4] [Cited by in Crossref: 217] [Cited by in F6Publishing: 216] [Article Influence: 72.3] [Reference Citation Analysis]
583 Rabe JL, Gardner L, Hunter R, Fonseca JA, Dougan J, Gearheart CM, Leibowitz MS, Lee-Miller C, Baturin D, Fosmire SP, Zelasko SE, Jones CL, Slansky JE, Rupji M, Dwivedi B, Henry CJ, Porter CC. IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression. Cancer Res 2019;79:3702-13. [PMID: 31142509 DOI: 10.1158/0008-5472.CAN-18-3800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
584 Chua KLM, Fehlings M, Yeo ELL, Nardin A, Sumatoh H, Chu PL, Nei WL, Ong EHW, Woo WY, Low KP, Wang H, Poon DJJ, Liang ZG, Yao K, Huang L, Toh CK, Ang MK, Farid M, Cheng XM, Kanesvaran R, Dent R, Wee JTS, Lim TKH, Iyer NG, Tan DSW, Soo KC, Newell EW, Chua MLK. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. Int J Radiat Oncol Biol Phys 2020;108:70-80. [PMID: 32544576 DOI: 10.1016/j.ijrobp.2020.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
585 Ylösmäki E, Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy. Curr Opin Biotechnol 2020;65:25-36. [PMID: 31874424 DOI: 10.1016/j.copbio.2019.11.016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
586 Chauhan VP, Chen IX, Tong R, Ng MR, Martin JD, Naxerova K, Wu MW, Huang P, Boucher Y, Kohane DS, Langer R, Jain RK. Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. Proc Natl Acad Sci U S A 2019;116:10674-80. [PMID: 31040208 DOI: 10.1073/pnas.1819889116] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 21.0] [Reference Citation Analysis]
587 Westhoff MA, Marschall N, Debatin KM. Novel Approaches to Apoptosis-Inducing Therapies. Adv Exp Med Biol 2016;930:173-204. [PMID: 27558822 DOI: 10.1007/978-3-319-39406-0_8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
588 Kelderman S, Kvistborg P. Tumor antigens in human cancer control. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2016;1865:83-9. [DOI: 10.1016/j.bbcan.2015.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
589 Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. Oral Oncology 2016;52:1-10. [DOI: 10.1016/j.oraloncology.2015.11.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 6.3] [Reference Citation Analysis]
590 Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res 2017;5:357-62. [PMID: 28396509 DOI: 10.1158/2326-6066.CIR-16-0287] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
591 Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 2018;7:e1509819. [PMID: 30377572 DOI: 10.1080/2162402X.2018.1509819] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
592 Liu JR, Yu CW, Hung PY, Hsin LW, Chern JW. High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma. Biochem Pharmacol 2019;163:458-71. [PMID: 30885763 DOI: 10.1016/j.bcp.2019.03.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
593 Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462-472. [PMID: 25858805 DOI: 10.1016/j.ccell.2015.02.015] [Cited by in Crossref: 647] [Cited by in F6Publishing: 621] [Article Influence: 92.4] [Reference Citation Analysis]
594 Wang L, Yao R, Zhang L, Fan C, Ma L, Liu J. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. Int Immunopharmacol 2019;70:498-503. [PMID: 30875561 DOI: 10.1016/j.intimp.2019.01.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
595 Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav DK, Bai X, Liang T. Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol 2020;4:29. [PMID: 33299118 DOI: 10.1038/s41698-020-00136-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
596 Hah YS, Koo KC. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci 2021;22:4452. [PMID: 33923219 DOI: 10.3390/ijms22094452] [Reference Citation Analysis]
597 Collazo-Lorduy A, Galsky MD. Combining chemotherapy and immune checkpoint blockade. Curr Opin Urol 2016;26:508-13. [PMID: 27517639 DOI: 10.1097/MOU.0000000000000333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
598 Li J, Gu J. Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. Immunotherapy 2018;10:1293-302. [PMID: 30474476 DOI: 10.2217/imt-2018-0116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
599 Deshpande RP, Sharma S, Watabe K. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers (Basel) 2020;12:E2983. [PMID: 33076303 DOI: 10.3390/cancers12102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
600 Cho SY, Huff DT, Jeraj R, Albertini MR. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Semin Nucl Med 2020;50:518-31. [PMID: 33059821 DOI: 10.1053/j.semnuclmed.2020.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
601 Young MH, Pietz G, Whalen E, Copeland W, Thompson E, Fox BA, Newhall KJ. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Sci Rep 2021;11:16460. [PMID: 34385543 DOI: 10.1038/s41598-021-95902-x] [Reference Citation Analysis]
602 Skibinski DA. Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples. Future Oncol 2018;14:1237-40. [PMID: 29712488 DOI: 10.2217/fon-2018-0150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
603 Nakayama Y, Mimura K, Kua L, Okayama H, Min AKT, Saito K, Hanayama H, Watanabe Y, Saito M, Momma T, Saze Z, Ohki S, Suzuki Y, Ichikawa D, Yong W, Kono K. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. Gastric Cancer 2020;23:961-73. [DOI: 10.1007/s10120-020-01079-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
604 Buder-Bakhaya K, Hassel JC. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. Front Immunol 2018;9:1474. [PMID: 30002656 DOI: 10.3389/fimmu.2018.01474] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 26.0] [Reference Citation Analysis]
605 Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.Eur Respir J. 2020;55. [PMID: 32451346 DOI: 10.1183/13993003.00953-2019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 19.0] [Reference Citation Analysis]
606 Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. J Immunother Cancer 2019;7:194. [PMID: 31337426 DOI: 10.1186/s40425-019-0675-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
607 Suresh S, Chen B, Zhu J, Golden RJ, Lu C, Evers BM, Novaresi N, Smith B, Zhan X, Schmid V, Jun S, Karacz CM, Peyton M, Zhong L, Wen Z, Sathe AA, Xing C, Behrens C, Wistuba II, Xiao G, Xie Y, Fu YX, Minna JD, Mendell JT, O'Donnell KA. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer 2020;1:533-45. [PMID: 32984844 DOI: 10.1038/s43018-020-0056-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
608 Vokes NI, Van Allen EM. Tumor Evolution: A Problem of Histocompatibility. Cell 2017;171:1252-3. [PMID: 29195070 DOI: 10.1016/j.cell.2017.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
609 Jin J, Zhao Q. Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. J Nanobiotechnology 2020;18:75. [PMID: 32408880 DOI: 10.1186/s12951-020-00629-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
610 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Reference Citation Analysis]
611 Haitz K, Khosravi H, Lin JY, Menge T, Nambudiri VE. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma. J Am Acad Dermatol 2020;83:189-96. [PMID: 32004650 DOI: 10.1016/j.jaad.2020.01.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
612 Ninomiya K, Hotta K. Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opin Biol Ther 2018;18:1015-21. [PMID: 30207786 DOI: 10.1080/14712598.2018.1522300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
613 Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging 2017;44:2310-25. [PMID: 28815334 DOI: 10.1007/s00259-017-3802-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
614 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Reference Citation Analysis]
615 Attrill GH, Ferguson PM, Palendira U, Long GV, Wilmott JS, Scolyer RA. The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell Melanoma Res 2021;34:529-49. [PMID: 32939993 DOI: 10.1111/pcmr.12926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR. Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. Prostate 2017;77:1478-88. [DOI: 10.1002/pros.23424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
617 Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells. Hum Immunol 2021;82:130-8. [PMID: 33341289 DOI: 10.1016/j.humimm.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
618 Du K, Wei S, Wei Z, Frederick DT, Miao B, Moll T, Tian T, Sugarman E, Gabrilovich DI, Sullivan RJ, Liu L, Flaherty KT, Boland GM, Herlyn M, Zhang G. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat Commun 2021;12:6023. [PMID: 34654806 DOI: 10.1038/s41467-021-26299-4] [Reference Citation Analysis]
619 Castellarin M, Watanabe K, June CH, Kloss CC, Posey AD Jr. Driving cars to the clinic for solid tumors. Gene Ther 2018;25:165-75. [PMID: 29880908 DOI: 10.1038/s41434-018-0007-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
620 Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ. Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer? Am Soc Clin Oncol Educ Book 2019;39:564-71. [PMID: 31099689 DOI: 10.1200/EDBK_243071] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
621 Kim JY, Kronbichler A, Eisenhut M, Hong SH, van der Vliet HJ, Kang J, Shin JI, Gamerith G. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1798. [PMID: 31731749 DOI: 10.3390/cancers11111798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
622 Maybruck BT, Pfannenstiel LW, Diaz-Montero M, Gastman BR. Tumor-derived exosomes induce CD8+ T cell suppressors. J Immunother Cancer 2017;5:65. [PMID: 28806909 DOI: 10.1186/s40425-017-0269-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 14.8] [Reference Citation Analysis]
623 Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, Widmaier M, Rebelatto MC, Kaplon H, Damotte D, Alifano M, Hammond SA, Dieu-Nosjean MC, Ranade K, Schmidt G, Higgs BW, Steele KE. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. J Immunother Cancer 2019;7:121. [PMID: 31060602 DOI: 10.1186/s40425-019-0589-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
624 Cummings AL, Garon EB. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med 2017;14:341-7. [PMID: 29372100 DOI: 10.20892/j.issn.2095-3941.2017.0090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
625 Bauer C, Kühnemuth B, Duewell P, Ormanns S, Gress T, Schnurr M. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters 2016;381:259-68. [DOI: 10.1016/j.canlet.2016.02.057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
626 JiaWei Z, ChunXia D, CunDong L, Yang L, JianKun Y, HaiFeng D, Cheng Y, ZhiPeng H, HongYi W, DeYing L, ZhiJian L, Xiao X, QiZhao Z, KangYi X, WenBing G, Ming X, JunHao Z, JiMing B, ShanChao Z, MingKun C. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer. Ann Med 2021;53:730-40. [PMID: 34032524 DOI: 10.1080/07853890.2021.1924396] [Reference Citation Analysis]
627 Page DB, Diab A, Yuan J, Dong Z, Soloman SB, Patil S, Hudis CA, Wolchok JD, Norton L, Mcarthur HL. Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients. j immunotherapy cancer 2015;3. [DOI: 10.1186/2051-1426-3-s1-o6] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
628 Huang KC, Chiang SF, Chen WT, Chen TW, Hu CH, Yang PC, Ke TW, Chao KSC. Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer. Cancers (Basel) 2020;12:E462. [PMID: 32079180 DOI: 10.3390/cancers12020462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
629 Lee J, Long G, Boyd S, Lo S, Menzies A, Tembe V, Guminski A, Jakrot V, Scolyer R, Mann G, Kefford R, Carlino M, Rizos H. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology 2017;28:1130-6. [DOI: 10.1093/annonc/mdx026] [Cited by in Crossref: 152] [Cited by in F6Publishing: 138] [Article Influence: 30.4] [Reference Citation Analysis]
630 Jin J, Zhao Q. Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration. Theranostics 2020;10:6231-44. [PMID: 32483450 DOI: 10.7150/thno.45219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
631 Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH, Ploegh HL, Dougan SK. Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs. Cancer Immunol Res 2018;6:389-401. [PMID: 29459478 DOI: 10.1158/2326-6066.CIR-17-0495] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
632 LoRusso PM, Schalper K, Sosman J. Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. Pigment Cell Melanoma Res 2020;33:390-402. [PMID: 31705737 DOI: 10.1111/pcmr.12847] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
633 Li X, Gruosso T, Zuo D, Omeroglu A, Meterissian S, Guiot MC, Salazar A, Park M, Levine H. Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A 2019;116:3678-87. [PMID: 30733298 DOI: 10.1073/pnas.1817652116] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
634 Zhang R, Xu T, Xia Y, Wang Z, Li X, Chen W. ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer. Front Oncol 2020;10:581733. [PMID: 33680917 DOI: 10.3389/fonc.2020.581733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
635 Ji S, Li J, Chang L, Zhao C, Jia R, Tan Z, Liu R, Zhang Y, Li Y, Yin G, Guan Y, Xia X, Yi X, Xu J. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor. Clin Transl Oncol 2021;23:1646-56. [PMID: 33583004 DOI: 10.1007/s12094-021-02562-4] [Reference Citation Analysis]
636 Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655-61. [PMID: 30297911 DOI: 10.1038/s41591-018-0198-0] [Cited by in Crossref: 271] [Cited by in F6Publishing: 253] [Article Influence: 67.8] [Reference Citation Analysis]
637 Martin D, Rödel F, Balermpas P, Rödel C, Fokas E. The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2017;1868:221-30. [DOI: 10.1016/j.bbcan.2017.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
638 Watkins TS, Miles JJ. The human T-cell receptor repertoire in health and disease and potential for omics integration. Immunol Cell Biol 2021;99:135-45. [PMID: 32677130 DOI: 10.1111/imcb.12377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
639 [DOI: 10.1101/2020.04.28.066639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
640 Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J Leukoc Biol 2016;100:275-90. [PMID: 27256570 DOI: 10.1189/jlb.5RI0116-013RR] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
641 Rogava M, Izar B. CXCR3: Here to stay to enhance cancer immunotherapy? EBioMedicine 2019;49:11-2. [PMID: 31690542 DOI: 10.1016/j.ebiom.2019.09.044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
642 Wilhelm J, Wang Z, Sumer BD, Gao J. Exploiting nanoscale cooperativity for precision medicine. Adv Drug Deliv Rev 2020;158:63-72. [PMID: 32882321 DOI: 10.1016/j.addr.2020.08.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
643 Veldman J, Visser L, Berg AVD, Diepstra A. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treatment Reviews 2020;82:101931. [DOI: 10.1016/j.ctrv.2019.101931] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
644 Cui J, Wang H, Medina R, Zhang Q, Xu C, Indig IH, Zhou J, Song Q, Dmitriev P, Sun MY, Guo L, Wang Y, Rosenblum JS, Kovach JS, Gilbert MR, Zhuang Z. Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. Cancers (Basel) 2020;12:E139. [PMID: 31935881 DOI: 10.3390/cancers12010139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
645 Lan Q, Ji C, Yao Y. [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC]. Zhongguo Fei Ai Za Zhi 2019;22:512-9. [PMID: 31451142 DOI: 10.3779/j.issn.1009-3419.2019.08.06] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
646 Sawada L, Vallinoto ACR, Brasil-Costa I. Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein-Barr Virus. Biomolecules 2021;11:1792. [PMID: 34944437 DOI: 10.3390/biom11121792] [Reference Citation Analysis]
647 Kluger HM, Zito CR, Turcu G, Baine MK, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 2017;23:4270-9. [PMID: 28223273 DOI: 10.1158/1078-0432.CCR-16-3146] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 15.4] [Reference Citation Analysis]
648 Xie Y, Olkhov-Mitsel E, Alminawi S, Slodkowska E, Downes MR. Development of a multiplex immuno-oncology biomarker and digital pathology workflow for assessment of urothelial carcinoma. Pathol Res Pract 2021;226:153607. [PMID: 34509050 DOI: 10.1016/j.prp.2021.153607] [Reference Citation Analysis]
649 Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci 2020;27:77. [PMID: 32620165 DOI: 10.1186/s12929-020-00670-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
650 Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang M, Li H, Li P, Zhang Y, Zhang Q. TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas. Cancer Manag Res 2019;11:4743-56. [PMID: 31191027 DOI: 10.2147/CMAR.S203156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
651 Peng S, Zaretsky JM, Ng AHC, Chour W, Bethune MT, Choi J, Hsu A, Holman E, Ding X, Guo K, Kim J, Xu AM, Heath JE, Noh WJ, Zhou J, Su Y, Lu Y, McLaughlin J, Cheng D, Witte ON, Baltimore D, Ribas A, Heath JR. Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood. Cell Rep 2019;28:2728-2738.e7. [PMID: 31484081 DOI: 10.1016/j.celrep.2019.07.106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
652 Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis 2017;56:221-8. [PMID: 28163164 DOI: 10.1016/j.ijid.2017.01.028] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 14.0] [Reference Citation Analysis]
653 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22:26-36. [PMID: 26735408 DOI: 10.1038/nm.4015] [Cited by in Crossref: 216] [Cited by in F6Publishing: 206] [Article Influence: 36.0] [Reference Citation Analysis]
654 Deng D, Luo X, Zhang S, Xu Z. Immune cell infiltration-associated signature in colon cancer and its prognostic implications. Aging (Albany NY) 2021;13:19696-709. [PMID: 34349038 DOI: 10.18632/aging.203380] [Reference Citation Analysis]
655 Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. Nat Rev Dis Primers 2015;1:15003. [PMID: 27188223 DOI: 10.1038/nrdp.2015.3] [Cited by in Crossref: 212] [Cited by in F6Publishing: 203] [Article Influence: 30.3] [Reference Citation Analysis]
656 Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, Zhang Y, Liu P, Zhang Y, Li C, Chu Y, Sun T, Jiang C. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials 2021;268:120546. [PMID: 33253966 DOI: 10.1016/j.biomaterials.2020.120546] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
657 Matsuda A, Ishiguro K, Yan IK, Patel T. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. Hepatol Commun 2019;3:525-41. [PMID: 30976743 DOI: 10.1002/hep4.1311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
658 Shanavas M, Law SC, Hertzberg M, Hicks RJ, Seymour JF, Li Z, Merida de Long L, Nath K, Sabdia MB, Gunawardana J, Gandhi MK, Keane C. Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. Clin Transl Immunology 2021;10:e1351. [PMID: 34745610 DOI: 10.1002/cti2.1351] [Reference Citation Analysis]
659 Hu A, Ding M, Zhu J, Liu JQ, Pan X, Ghoshal K, Bai XF. Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy. Front Cell Dev Biol 2020;8:210. [PMID: 32292786 DOI: 10.3389/fcell.2020.00210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
660 Hamada T, Keum N, Nishihara R, Ogino S. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017;52:265-275. [PMID: 27738762 DOI: 10.1007/s00535-016-1272-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
661 Filipovic A, Miller G, Bolen J. Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. Front Cell Dev Biol 2020;8:155. [PMID: 32258034 DOI: 10.3389/fcell.2020.00155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
662 Mouw KW, D’andrea AD. DNA Repair Deficiency and Immunotherapy Response. JCO 2018;36:1710-3. [DOI: 10.1200/jco.2018.78.2425] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
663 Kim A, Han CJ, Driver I, Olow A, Sewell AK, Zhang Z, Ouyang W, Egen JG, Yu X. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells. J Immunol 2019;203:1076-87. [PMID: 31253728 DOI: 10.4049/jimmunol.1801472] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
664 Kim HM, Lee J, Koo JS. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer 2017;17:690. [PMID: 29041905 DOI: 10.1186/s12885-017-3670-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
665 Ma Z, Shiao SL, Yoshida EJ, Swartwood S, Huang F, Doche ME, Chung AP, Knudsen BS, Gertych A. Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. Diagn Pathol 2017;12:69. [PMID: 28923066 DOI: 10.1186/s13000-017-0658-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
666 Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 2017;130:2265-70. [PMID: 29167175 DOI: 10.1182/blood-2017-06-781989] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
667 Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res 2019;79:1214-25. [PMID: 30541742 DOI: 10.1158/0008-5472.CAN-18-1127] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
668 Kwak Y, Koh J, Park Y, Hong YJ, Park KU, Kim HH, Park DJ, Ahn SH, Kim WH, Lee HS. Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer 2020;122:1399-408. [PMID: 32203213 DOI: 10.1038/s41416-020-0793-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
669 Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open 2018;3:e000257. [PMID: 29344407 DOI: 10.1136/esmoopen-2017-000257] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
670 Brouwer TP, Vahrmeijer AL, de Miranda NFCC. Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. Cell Oncol (Dordr) 2021;44:261-78. [PMID: 33710604 DOI: 10.1007/s13402-021-00587-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
671 Sato M, Umeda Y, Tsujikawa T, Mori T, Morikawa M, Anzai M, Waseda Y, Kadowaki M, Kiyono Y, Okazawa H, Ishizuka T. Predictive value of 3'-deoxy-3'-18F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. J Immunother Cancer 2021;9:e003079. [PMID: 34301816 DOI: 10.1136/jitc-2021-003079] [Reference Citation Analysis]
672 Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol. 2015;42:663-671. [PMID: 26320069 DOI: 10.1053/j.seminoncol.2015.05.011] [Cited by in Crossref: 229] [Cited by in F6Publishing: 227] [Article Influence: 32.7] [Reference Citation Analysis]
673 Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015;36:587-95. [PMID: 26162965 DOI: 10.1016/j.tips.2015.06.005] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 14.4] [Reference Citation Analysis]
674 Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H. Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary. Ann Oncol 2021:S0923-7534(21)04824-9. [PMID: 34843940 DOI: 10.1016/j.annonc.2021.11.009] [Reference Citation Analysis]
675 Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00427-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
676 García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5134. [PMID: 34680282 DOI: 10.3390/cancers13205134] [Reference Citation Analysis]
677 Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandalà M. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients. Eur J Cancer 2017;78:70-81. [PMID: 28412591 DOI: 10.1016/j.ejca.2017.03.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
678 Miranda-Galvis M, Rumayor Piña A, Sales de Sá R, Almeida Leite A, Agustin Vargas P, Calsavara VF, Lópes Pinto CA, Teng Y, Kowalski LP. PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification. Oral Dis 2020. [PMID: 33169454 DOI: 10.1111/odi.13714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
679 Schilling B, Griewank KG. [Molecular and immunohistochemical diagnostics in melanoma]. Hautarzt 2016;67:511-8. [PMID: 27270408 DOI: 10.1007/s00105-016-3807-1] [Cited by in Crossref: 2] [